Office of Management and Budget Circular A-133 Reports For The Year Ended June 30, 2011

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

	Page
INDEPENDENT AUDITORS' REPORT	1
COMBINED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2011 AND 2010:	
Combined Balance Sheets	2
Combined Statements of Operations and Changes in Net Assets	3-4
Combined Statements of Cash Flows	5
Notes to Combined Financial Statements	6-31
SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2011	32-45
NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2011	46
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS	47
REPORT ON COMPLIANCE WITH REQUIREMENTS THAT COULD HAVE A DIRECT AND MATERIAL EFFECT ON EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE IN ACCORDANCE WITH OMB CIRCULAR A-133	48-49
SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2011 AND 2010	50-51



Deloitte & Touche LLP 250 E. 5th Street Suite 1900 Cincinnati, OH 45202-5109 USA

Tel: +1 513 784 7100 Fax: +1 513 784 7204 www.deloitte.com

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates: Cincinnati, Ohio

We have audited the accompanying combined balance sheets of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") as of June 30, 2011 and 2010, and the related combined statements of operations and changes in net assets and of cash flows for the years then ended. The combined financial statements include the accounts of Children's Hospital Medical Center and the affiliated entities as discussed in Note 1(a). These entities are under common ownership and management. These financial statements are the responsibility of Cincinnati Children's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Cincinnati Children's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such financial statements present fairly, in all material respects, the financial position of Cincinnati Children's as of June 30, 2011 and 2010, and the combined results of their operations and their combined cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were performed for the purpose of forming an opinion on the basic combined financial statements taken as a whole. The accompanying schedule of expenditures of federal awards is presented for the purpose of additional analysis as required by U.S. Offices of Management and Budget Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations,* and is not a required part of the basic combined financial statements. This schedule is the responsibility of the management of Cincinnati Children's. Such information has been subjected to the auditing procedures applied in our audit of the basic 2011 combined financial statements and, in our opinion, is fairly stated in all material respects when considered in relation to the basic 2011 combined financial statements taken as a whole.

In accordance with *Government Auditing Standards*, we have also issued our report dated October 25, 2011 on our consideration of Cincinnati Children's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* and should be considered in assessing the results of our 2011 audit.

Deloite & Tarche LLP

October 25, 2011

Combined Balance Sheets June 30, 2011 and 2010 (dollars in thousands)

	2011	2010
CURRENT ASSETS:		
Cash and cash equivalents	\$ 97,451	\$ 85,813
Marketable securities	227,642	186,451
Cash, cash equivalents and marketable securities	325,093	272,264
Patient receivables, net of allowances of \$39,687 in 2011 and \$36,989 in 2010	204,081	216,901
Other receivables, net	98,711	88,213
Inventories and prepaid expenses	23,811	19,472
Total current assets	651,696	596,850
ASSETS LIMITED AS TO USE - Funds in trust	4,620	5,569
PROPERTY AND EQUIPMENT, at cost,		
net of accumulated depreciation	851,701	846,129
DEFERRED BOND ISSUANCE COSTS AND OTHER	74,261	67,790
INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS (Note 1(b))	886,162	694,102
Total assets	\$2,468,440	\$2,210,440
CURRENT LIABILITIES:		_
Accounts payable and accrued expenses	\$ 188,643	\$ 189,444
Current portion of long-term debt and capital lease obligations	19,432	15,716
Total current liabilities	208,075	205,160
ACCRUED PENSION BENEFIT LIABILITY (Note 9)	201,760	275,842
SELF-INSURANCE RESERVES	30,545	24,292
LONG-TERM DEBT:	450.054	471.504
Bonds payable	450,964	471,526
Note payable Capital lease obligations	27,155 3,352	2,294
OTHER LONG-TERM LIABILITIES	12,734	8,812
Total liabilities	934,585	987,926
COMMITMENTS AND CONTINGENCIES (Notes 6 and 10)	-	-
NET ASSETS:		
Unrestricted	526,991	410,760
Temporarily restricted	135,943	131,062
Permanently restricted (Note 1(b))	870,921	680,692
Total liabilities and not assets	1,533,855	1,222,514
Total liabilities and net assets	\$2,468,440	\$2,210,440
See accompanying notes to financial statements.		

Combined Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2011 and 2010 (dollars in thousands)

	2011	2010
UNRESTRICTED REVENUES, GAINS AND OTHER SUPPORT:		
Net hospital patient service revenue	\$1,144,142	\$1,093,617
Professional services revenue	229,749	214,307
Net assets released from restriction used for operations-	,	,
Grant revenue	153,914	143,011
Other restricted net assets used to support operations	78,546	73,729
Investment income	13,814	16,374
Other revenue	73,243	62,829
Total unrestricted revenues, gains and other support	1,693,408	1,603,867
EXPENSES:		
Salaries	797,449	755,513
Employee benefits	236,374	207,744
Supplies, drugs and other	287,185	266,618
Purchased services	174,349	171,275
Depreciation	110,716	105,107
Utilities	17,858	17,452
Interest	16,104	15,729
Total expenses	1,640,035	1,539,438
Excess of revenues over expenses	53,373	64,429
OTHER CHANGES IN UNRESTRICTED NET ASSETS:		
Receipts from supporting organizations (Notes 1(b) and 1(c))	5,595	7,798
Net assets released from restrictions used for purchase of property and equipment	5,559	3,220
Increase in unrestricted net assets before transfers to		_
supporting organizations and pension and post		
retirement health liability adjustment	64,527	75,447
Transfers to supporting organizations (Note 1(c))	(15,575)	(10,560)
Pension and post retirement health liability adjustment (Note 9)	67,279	(55,280)
Increase in unrestricted net assets	116,231	9,607

(Continued on next page)

Combined Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2011 and 2010 (dollars in thousands)

	2011	2010
TEMPORARILY RESTRICTED NET ASSETS:		
Contributions and investment income-		
Grant receipts	151,652	132,486
Industry support	1,937	6,648
Gifts, contributions and other income	87,860	96,479
	241,449	235,613
Net assets released from restriction-		
Grant expenditures	(153,914)	(143,011)
Transfer to The Children's Hospital	(795)	(1,159)
Restricted net assets used to support operations	(78,546)	(73,729)
Restricted net assets used for purchase of property and equipment	(5,559)	(3,220)
	(238,814)	(221,119)
Gain in interest in net assets of supporting organizations	2,246	974
Increase in temporarily restricted net assets	4,881	15,468
PERMANENTLY RESTRICTED NET ASSETS:		
Gain in interest in net assets of supporting organizations	190,229	57,630
Increase in permanently restricted net assets	190,229	57,630
INCREASE IN NET ASSETS	311,341	82,705
NET ASSETS, beginning of year	1,222,514	1,139,809
NET ASSETS, end of year	\$1,533,855	\$1,222,514

See accompanying notes to financial statements.

Combined Statements of Cash Flows For the Years Ended June 30, 2011 and 2010 (dollars in thousands)

	2011	2010
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	\$ 311,341	\$ 82,705
Adjustments to reconcile increase in net assets to net cash provided by	+ ,	+,
operating activities-		
Depreciation and amortization	111,175	105,398
Loss on disposal of property and equipment	1,270	161
Contributions to supporting organizations, net	9,980	2,762
Contributions restricted for purchase of property and equipment	(5,559)	(3,220)
Gain in interest in net assets of supporting organizations	(192,475)	(58,604)
Receipts from The Children's Hospital Foundation	415	183
Unrealized and realized gains on marketable securities, net Increase in allowance for doubtful accounts	(2,969)	(10,788)
(Increase) Decrease in receivables	2,698 (376)	12,847
Increase in inventories and prepaid expenses and other assets	(11,269)	(11,318)
Decrease in accounts payable and accrued expenses	(2,251)	(23,362)
(Decrease) Increase in accrued pension liability	(74,082)	36,340
Increase (Decrease) in self-insurance reserves and other long-term	(7.1,002)	30,310
liabilities	8,275	(2,009)
Net cash provided by operating activities	156,173	131,095
CASH FLOWS FROM INVESTING ACTIVITIES:		
Expenditures for property and equipment	(84,811)	(102,953)
Receipts from sale of fixed assets	711	804
Purchases of marketable securities	(680,350)	(674,482)
Sales of marketable securities	642,824	630,821
Cash withdrawn from funds in trust	60,079	75,265
Cash invested in funds in trust	(59,130)	(59,795)
Net cash used in investing activities	(120,677)	(130,240)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Issuance of bonds and notes payable	30,000	30,000
Repayment of bonds and notes payable	(49,437)	(45,162)
Contributions restricted for purchase of property and equipment	5,559	3,220
Contributions to supporting organizations, net	(9,980)	(2,762)
Net cash used in financing activities	(23,858)	(14,704)
Net increase (decrease) in cash and cash equivalents	11,638	(13,849)
CASH AND CASH EQUIVALENTS, beginning of year	85,813	99,662
CASH AND CASH EQUIVALENTS, end of year	\$ 97,451	\$ 85,813
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:		
Capital expenditures in accrued expenses and accounts payable	\$9,598	\$8,148

See accompanying notes to financial statements.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(1) Accounting Policies-

(a) <u>Basis of Combination</u>--Children's Hospital Medical Center (Cincinnati Children's), Convalescent Hospital for Children (CHC), River City Insurance Limited (River City), Children's Health Administrative Services LLC (CHAS), Children's Health Services Network (CHSN), Children's Medical Services, Inc. (CMSI), Northern Kentucky Children's Medical Services, LLC (NKCMS), Children's for Children LLC (CFC), Burnet Ave LLC (Burnet) and TSHCH LLC (TSHCH), which are under common management, are included in the accompanying combined financial statements and are collectively referred to as the Medical Center. Intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, teaching and related research. CHC is an Ohio not-for-profit corporation providing programmatic oversight, governance and fiscal management to chronic illness, mental health and traumatic and congenital brain injury programs at Cincinnati Children's. Cincinnati Children's and CHC are under common management. Subsequent to year-end, on July 28, 2011, CHC merged with and into Cincinnati Children's, Cincinnati Children's assumed all assets and liabilities of CHC and CHC ceases to exist as a separate entity. River City is a captive insurance company and a wholly-owned subsidiary of Cincinnati Children's. CHAS is a wholly-owned subsidiary of Cincinnati Children's whose purpose is to provide management services to members of the medical and dental staff. Effective March 31, 2011 CHAS was dissolved. CHSN is a wholly-owned subsidiary of Cincinnati Children's whose purpose is to manage primary care practices in a community setting. CMSI is a professional corporation whose purpose is to engage in the practice of medicine and render professional services and co-employs certain Cincinnati Children's physicians. Effective January 1, 2011 CMSI ceased operations. NKCMS is a limited liability corporation formed to enhance the scope and quality of pediatric care in Northern Kentucky. CFC was a wholly-owned subsidiary of Cincinnati Children's whose purpose was to operate child care programs. Effective January 1, 2010, CFC ceased operations. Burnet is a wholly-owned subsidiary of Cincinnati Children's, whose purpose is to hold land. TSHCH is a wholly-owned subsidiary of Cincinnati Children's whose purpose is to acquire, hold, develop, subdivide, sell, lease, mortgage, manage and otherwise deal in real property.

(b) <u>Supporting Organizations</u>--The Children's Hospital (TCH), The Children's Hospital Foundation (CHF), Convalescent Hospital for Children and Orphan Asylum (CHCOA), Adolescent Health Center of Greater Cincinnati, Inc. (CAC), and Children's Dental Care Foundation (CDCF), all Ohio not-for-profit corporations which are not included in the accompanying combined financial statements, provide financial support to the Medical Center. Certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of the Medical Center. Receipts from such restricted endowment funds and certain other receipts that are designated by the Boards of Trustees of the supporting organizations for specific operating purposes are reflected as a component of restricted gifts and contributions in the accompanying Combined Statements of Operations and Changes in Net Assets. Upon utilization in operations, such funds are reflected in the Combined Statements of Operations and Changes in Net Assets as donor-restricted revenue from supporting organizations.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

Other funds are contributed to the Medical Center as designated by the Boards of the supporting organizations to provide general support and are reflected as receipts from supporting organizations in the accompanying Combined Statements of Operations and Changes in Net Assets.

The Medical Center records in its combined financial statements the fair value of certain permanently and temporarily restricted net assets held by supporting organizations on the Medical Center's behalf. Changes in the fair value of such temporarily and permanently restricted net assets are recorded as gain in interest in net assets of supporting organizations in the accompanying Combined Statements of Operations and Changes in Net Assets.

(c) Support Received from Supporting Organizations--

In general, the supporting organizations provide annual support to the Medical Center that includes the dividend and interest earnings of the respective investment portfolios (net of operational expenses and any donor required reinvestment of income). On occasion, the respective Boards of Trustees of these supporting organizations may also designate certain pledges of unrestricted principal in support of key projects at the Medical Center. As of June 30, 2011, TCH and CHCOA have outstanding revocable pledges of \$15,087 and \$5,000, respectively. All outstanding pledges of principal support are revocable at the discretion of TCH's and CHCOA's Board of Trustees. As a result, such revocable pledges are not recorded as receivables in the accompanying combined financial statements.

During fiscal 2011 and 2010, TCH transferred \$68,329 and \$70,746, respectively, of temporarily restricted net assets to the Medical Center which are recorded as Gifts, contributions and other income in the Combined Statements of Operations and Changes in Net Assets.

During fiscal 2011 and 2010, TCH transferred \$5,595 and \$7,798, respectively, of unrestricted net assets to the Medical Center, which are recorded as Receipts from Supporting Organizations in the Combined Statements of Operations and Changes in Net Assets.

During fiscal 2011 and 2010, the Medical Center transferred \$795 and \$1,159, respectively, of temporarily restricted net assets to TCH to fund named chairs designated to support divisional activities. During fiscal 2011 and fiscal 2010, respectively, the Medical Center transferred \$9,325 and \$8,550 of unrestricted net assets to TCH to fund named chairs to support divisional activities.

At June 30, 2011 the Medical Center has a receivable from TCH for \$8,526 related to fiscal 2011 unfunded irrevocable commitments. This amount will be received in fiscal 2012. Additionally, the Medical Center has a payable to TCH at June 30, 2011 of \$439 for contributions received at the Medical Center at year-end for which the cash needs to be transferred to TCH.

At June 30, 2010, the Medical Center had a payable to TCH for \$2,464 for an advance of cash TCH made to the Medical Center. The amount was paid to TCH in fiscal 2011.

During fiscal 2011 and 2010, CHCOA transferred \$2,721 and \$2,639, respectively, of unrestricted net assets to the Medical Center which are recorded as Gifts, contributions and other income in the Combined Statements of Operations and Changes in Net Assets.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

At June 30, 2011, the Medical Center has a receivable from CHCOA for \$268 related to fiscal 2011 unfunded commitments. This amount will be received in fiscal 2012.

During fiscal 2011 and 2010, CHF transferred \$992 and \$647, respectively, of temporarily restricted net assets to the Medical Center, which are recorded as Gifts, contributions and other income in the Combined Statements of Operations and Changes in Net Assets.

During fiscal 2011 and fiscal 2010, respectively, the Medical Center transferred \$6,250 and \$2,000 of unrestricted net assets to CHF and the income earned on the funds will be transferred back to the Divisions to support divisional activities.

The Medical Center has a note receivable from CHF for \$10,264 at June 30, 2011 and 2010, which is recorded in other receivables in the accompanying Combined Balance Sheets.

(d) <u>Concentration of Patient Accounts Receivable and Revenue and Revenue Recognition</u>--In both fiscal 2011 and 2010, respectively, substantially all of total net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements).

The following details the percentage of net patient service revenue by payor category for the fiscal years ended June 30, 2011 and 2010:

	2011		2010)
	Gross	Net	Gross	Net
Commercial insurers	1%	1%	1%	1%
Managed care	49%	68%	49%	65%
Medicaid (HMO and third party)	44%	25%	43%	28%
Specialty payors	5%	6%	6%	6%
Self pay	1%	- %	1%	- %

The following details the percentage of accounts receivable by payor category as of June 30, 2011 and 2010:

	2011	2010
Commercial insurers	1%	1%
Managed care	56%	54%
Medicaid (HMO and third party)	29%	33%
Specialty payors	11%	9%
Self pay	3%	3%

Net patient service revenue is reported at estimated net realizable amounts from patients, third party payors and others for services rendered and includes estimated retroactive revenue adjustments due to future audits and reviews. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits and reviews.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

Revenue from Medicaid programs accounted for approximately 25% and 28% of the Medical Center's net patient service revenue for the fiscal year ended June 30, 2011 and 2010, respectively. Laws and regulations governing the Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change a material amount in the near term. At June 30, 2011, the Medical Center has settled all Medicaid cost reports through 2006.

The following table reconciles gross patient service revenue to net patient service revenue for the years ended June 30, 2011 and 2010:

	2011	2010
Charges at established rates	\$1,918,124	\$1,740,283
Deductions:		
Discounts on commercial contractuals	(168,070)	(168,635)
Write-downs related to services to the poor:		
Including Medicaid and governmental		
contractuals, charity care and other	(400.000)	(40.4.0=0)
uncollectible self pay write-offs	(623,977)	(494,379)
	1,126,077	1,077,269
Tax Levy Program	6,000	6,000
Care Assurance Program	12,065	10,348
	\$1,144,142	\$1,093,617

Physician professional fees, which have been assigned to the Medical Center and are required to be used in the respective physicians' department at the Medical Center, are recognized as revenue as billed. See footnote 10(c).

- (e) Grant Revenue and Other Revenue -- Grants and contributions restricted for a specific operating purpose are recorded as temporarily restricted net assets and reflected in unrestricted revenues, gains, and other support when the funds are expended in accordance with the specifications of the grantor or donor. Contributions for capital expenditures, recorded as temporarily restricted net assets when received, are recorded as net assets released from restrictions when expended. Unrestricted contributions and bequests are included in other revenue when received.
- (f) <u>Graduate Medical Education</u> --The Medical Center receives Federal graduate medical education funding, which has resulted in other revenue of \$9,578 and \$11,763 recognized in the accompanying combined financial statements for the years ended June 30, 2011 and 2010, respectively.
- (g) <u>Tax Exempt Status</u>—Cincinnati Children's, CHC, CHSN and CMSI are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. CHAS, NKMS, Burnet, TSHCH and CFC are limited liability corporations whose income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying combined financial statements are immaterial for the years ended June 30, 2011 and 2010.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The Medical Center accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is the Medical Center's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no penalties or interest accrued in fiscal 2011 and 2010.

Listed below are the tax years that remain subject to examination by major tax jurisdiction:

Federal – 2008 to 2011 State – 2008 to 2011

- (h) <u>Cash Equivalents</u>--Cash equivalents consist primarily of money market investments (including money market mutual funds), demand deposits and repurchase agreements. Cash is held primarily in one bank.
- (i) <u>Inventories</u>--Inventories consist of medical supplies and pharmaceuticals and are valued on an average cost method.
- (j) <u>Marketable Securities</u>--The Medical Center accounts for its investments under ASC 980 "Accounting for Certain Investments Held by Not-for-Profit Organizations". The Medical Center carries its marketable securities at fair value with unrealized gains and losses included in the Combined Statements of Operations and Changes in Net Assets. Fair value is determined by the trustee holding the assets based on published market prices.

The cost basis, approximate fair value and categorization by asset type at June 30, 2011 are as follows:

	Cost Basis	Gross Unrealized <u>Gains</u>	Gross Unrealized (<u>Losses)</u>	<u>Fair Value</u>
U.S. government and				
treasury obligations	\$115,800	\$1,072	\$ (345)	\$116,527
Municipal bonds and other	573	65	-	638
Variable rate demand notes	9,825	-	-	9,825
Corporate obligations	101,038	2,612	(2,998)	100,652
	\$227,236	\$3,749	\$(3,343)	\$227,642

The cost basis, approximate fair value and breakdown by asset type at June 30, 2010 are as follows:

	Cost Basis	Gross Unrealized <u>Gains</u>	Gross Unrealized (Losses)	<u>Fair Value</u>
U.S. government and treasury obligations	\$109,167	\$1,327	\$ (165)	\$110,329
Municipal bonds and other Corporate obligations	573 77,148 \$186,888	35 3,040 \$4,402	(4,674) \$ (4,839)	608 75,514 \$186,451

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The following is the maturities for marketable securities at June 30, 2011:

	Cost Basis	Fair Value
One year or less	\$ 1,972	\$ 1,996
One to five years	85,911	86,429
After five years	139,353	139,217
	\$227,236	\$227,642

At June 30, 2011, the Medical Center's marketable securities included 26% in U.S. Treasury securities and 17% in FNMA securities. At June 30, 2010, the Medical Center's marketable securities included 30% in U.S. Treasury securities and 21% in FNMA securities.

- (k) <u>Assets Limited As To Use</u>--Assets limited as to use include funds in trust (Note 4). Assets limited as to use are carried at fair value with unrealized gains and losses included in investment income in the accompanying Combined Statements of Operations and Changes in Net Assets. Fair value is determined by the trustee holding the assets based on published market prices. All assets limited as to use were held in cash and cash equivalents at June 30, 2011 and 2010.
- (l) <u>Investment Income</u>--The following details the components of investment income on marketable securities and funds in trust for the years ended June 30, 2011 and 2010:

	2011	2010
Interest income	\$11,266	\$10,287
Unrealized and realized gains, net	2,548	6,087
Investment income	\$13,814	\$16,374

Unrealized gains and losses related to temporarily restricted funds are recorded as an addition/reduction, as appropriate, to temporarily restricted net assets.

(m) <u>Fair Value Measurements</u>—The Medical Center accounts for its assets and liabilities under ASC 820 "Fair Value Measurements" (ASC 820).

As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Combined Financial Statements
For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using the Medical Center's estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, the Medical Center utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

In 2009, FASB Staff Position 157-4 "Disclosures Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions that are not orderly", was issued and later codified into ASC 820, which expanded disclosures and required that major category for debt and equity securities in the fair value hierarchy table be determined on the basis of the nature and the risks of the investments.

The table below includes the major categorization for debt and equity securities on the basis of the nature and risk of the investments at June 30, 2011.

	Level 1	Level 2	Level 3
Marketable Securities:			
U.S. Government and treasury securities	\$116,527	\$ -	\$ -
Municipal bonds	638	-	-
Variable rate demand notes	-	9,825	-
Corporate obligations	100,652	<u> </u>	-
	217,817	9,825	-

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

	Level 1	Level 2	Level 3
Investments in Limited Partnerships (included in Other Assets)			8,723
Investment in Fort Washington High Yield LLC (included in Other Assets)	_	21,680	_
Deferred Compensation Plans: (included in Other Assets and Accruals)		21,000	
Money Market Funds	1,904	-	-
Common Stock	2,156	-	-
Equity Mutual Funds	1,715	-	-
International Equity Mutual funds	793	-	-
Bond Mutual Funds	99	-	-
Fixed Income Mutual Funds	545	-	-
LifeCycle Mutual Funds	291	-	-
Real Estate Mutual Funds	110	-	-
Bond Variable Annuity	-	1,475	-
Equity Variable Annuity	-	2,933	-
Money Market Variable	-	99	-
Real Estate Pooled Separate Account	-	308	-
Guaranteed Insurance			1,694
	7,613	4,815	1,694
Total	\$225,430	\$36,320	\$10,417

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The table below includes the major categorization for debt and equity securities on the basis of the nature and risk of the investments at June 30, 2010.

	Level 1	Level 2	Level 3
Marketable Securities:			
U.S. Government and treasury securities	\$ 110,329	\$ -	\$ -
Municipal bonds	608	-	-
Corporate obligations	75,514		
	186,451		
Investments in Limited Partnerships (included in Other Assets)			7,317
Investment in Fort Washington High Yield LLC (included in Other Assets)		18,813	-
Deferred Compensation Plans: (included in Other Assets and Accruals)			
Money Market Funds	4,436	-	-
Common Stock	1,983	-	-
Equity Mutual Funds	1,135	-	-
International Equity Mutual funds	672	-	-
Bond Mutual Funds	53	-	-
Fixed Income Mutual	680	-	-
LifeCycle Mutual Funds	211	-	-
Real Estate Mutual Funds	77	-	-

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

	Level 1	Level 2	Level 3
Bond Variable Annuity	-	1,286	-
Equity Variable Annuity	-	2,232	-
Money Market Variable Annuity	-	254	-
Real Estate Pooled	-	243	-
Guaranteed Insurance			1,485
	9,247	4,015	1,485
Total	\$195,698	\$22,828	\$ 8,802

The valuation methods as described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

Investments in equity securities:

Investments in equity securities are typically valued at the closing price in the principal active market as of the last business day of the month. Principal active markets for equity prices include published exchanges such as NASDAQ, NYSE, NYMEX and Chicago Board of Trade, as well as pink sheets, which is an electronic quotation system that displays quotes for broker-dealers for many over-the-counter securities. Foreign equity prices are translated from their trading currency using the currency exchange rate in effect at the close of the principal active market. The Medical Center does not adjust prices to reflect for after-hours market activity.

Investments in debt securities:

Many debt investments are valued based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and consider the counterparty credit rating. Most debt valuations are Level 1 measures. If the market for a particular fixed income security is relatively inactive or illiquid, the measurement is a Level 3 measurement. U.S. Treasury debt is typically a Level 1 measurement.

In February 2007, the FASB issued ASC 825, "The Fair Value Option". ASC 825 permits entities to choose to measure many financial instruments and certain other items at fair value. Entities that elect the fair value option will report unrealized gains and losses in earnings at each subsequent reporting date. The Medical Center elected to measure its marketable securities under the provisions of ASC 825. However, in the future, the Medical Center may elect to measure certain additional financial instruments at fair value in accordance with this standard.

2010

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The following is a reconciliation of the rollforward of the fair value measurements using significant unobservable inputs for fiscal 2011:

Balance at July 1, 2010	\$ 8,802
Purchases	1,683
Unrealized gains	1,129
Unrealized losses	(1,197)
Balance at June 30, 2011	\$10,417
The amount of total gains or losses for the	
period included in changes in net assets	
attributable to the change in unrealized gains or	
losses related to assets still held at June 30,	
2011	\$(68)

The following is a reconciliation of the rollforward of the fair value measurements using significant unobservable inputs for fiscal 2010:

Balance at July 1, 2009	\$ 7,133
Purchases	1,859
Unrealized gains	644
Unrealized losses	(834)
Balance at June 30, 2010	\$ 8,802
The amount of total gains or losses for the	
period included in changes in net assets	
attributable to the change in unrealized gains or	
losses related to assets still held at June 30,	

In January 2010, the FASB issues ASU No. 2010-06 "Fair Value Measurements and Disclosures (ASU No. 2010-06), which amends ASC 820 adding new disclosure requirements for Levels 1 and 2 and separate disclosures of purchases, sales, issuances and settlements relating to Level 3 measurements and clarification of existing fair value disclosures. ASU No. 2010-06 is effective for periods beginning after December 15, 2009, except for the requirement to provide Level 3 activity of purchases, sales, issuances, and settlements on a gross basis, which will be effective for fiscal years beginning after December 15, 2010.

\$(190)

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(n) <u>Property and Equipment</u>--Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land Improvements	3-25 years
Buildings and Building Improvements	5-40 years
Equipment	3-30 years

Amortization of assets leased under capital leases is included in depreciation.

The Medical Center evaluates long-lived assets under the provisions of ASC 360 "Property Plant and Equipment". During fiscal 2011 and 2010, the Medical Center did not record any impairment losses.

(o) Costs of Borrowing--Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. Net capitalized interest during fiscal 2011 was approximately \$1,000. Net capitalized interest during fiscal 2010 was approximately \$15. Total cash paid for interest was approximately \$17,127 and \$15,706 and in fiscal 2011 and 2010, respectively.

Deferred bond issuance costs and original issue discounts are amortized using the effective interest method over the period the related obligation is outstanding.

(p) Temporarily Restricted Net Assets—Temporarily restricted net assets are those whose use by the Medical Center has been limited by donors to a specific purpose. Temporarily restricted net assets and net assets released from donor restrictions are primarily comprised of net assets restricted to support operations. Substantially all of these net assets are restricted by donors to support research, education and other advances in clinical care and prevention.

Temporarily restricted net assets related to assets held in endowments at supporting organizations on the Medical Center's behalf are either donor restricted to support research at the Medical Center's or deferred gift programs where the restriction is a time restriction tied to the life expectancy of the donor.

(q) Permanently Restricted Net Assets-Permanently restricted net assets are restricted by the donor to be maintained in perpetuity and are recorded in Interest in Net Assets of Supporting Organizations in the accompanying Combined Balance Sheets as they are held by supporting organizations. As of June 30, 2011 and 2010, permanently restricted net assets consisted of the following amounts with expendable investment income restricted by donors to be used for the following purposes:

	2011	2010
Research activities	\$722,192	\$554,245
Clinical activities	148,729	126,447
	\$870,921	\$680,692

The assets underlying the Medical Center's permanently restricted net assets have been invested by supporting organizations in marketable securities, including a significant concentration in the common stock of a consumer products company.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

- (r) Excess of Revenues Over Expenses--The Combined Statements of Operations and Changes in Net Assets include "excess of revenues over expenses." Changes in unrestricted net assets which are excluded from excess of revenues over expenses include receipts from supporting organizations, transfers to supporting organizations, pension and post retirement health liability adjustment, and contributions of long-lived assets (including assets acquired using contributions which by donor restrictions were to be used for the purpose of acquiring such assets).
- (s) <u>Use of Estimates</u>—The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(t) New Accounting Pronouncements--

In August 2010, the FASB issued ASU 2010-24, "Health Care Entities (Topic 954): Presentation of Insurance Claims and Recoveries," which provides clarification to companies in the healthcare industry on the accounting for professional liability insurance. ASU 2010-24 states that insurance liabilities should not be presented net of insurance recoveries and that an insurance receivable should be recognized on the same basis as the liabilities, subject to the need for a valuation allowance for uncollectible accounts. ASU 2010-24 is effective for fiscal years beginning after December 15, 2010. The Medical Center does not expect the adoption of the new guidance to have a material impact on the combined financial statements and related disclosures.

In May 2011, the FASB issued ASU 2011-4, "Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs," related to amendments to certain measurement principles and disclosures regarding fair value measurements. The amendments in this update improve the comparability of fair value measurements presented and disclosed in financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles and International Financial Reporting Standards. For nonpublic entities, the amendments are effective for annual periods beginning after December 15, 2011. The Medical Center does not expect the adoption of the new guidance to have a material impact on the combined financial statements and related disclosures.

In July 2011, the FASB issued ASU 2011-7, "Health Care Entities (Topic 954): Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities." In accordance with ASU 2011-7, the Medical Center will be required to present its provision for doubtful accounts as a deduction from revenue, similar to contractual discounts. Accordingly, the Medical Center's revenue will be required to be reported net of both contractual discounts and its provision for doubtful accounts. Additionally, ASU 2011-7 will require the Medical Center to make certain additional disclosures designed to help users understand how contractual discounts and bad debts affect recorded revenue in both interim and annual financial statements. ASU 2011-7 is required to be applied retrospectively; for nonpublic entities, the amendments are effective for the first annual period ending after December 15, 2012, and interim and annual periods thereafter, with early adoption permitted. The adoption of ASU 2011-7 is not expected to impact the Medical Center's financial position, results of operations or cash flows although it will

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

impact the presentation of the Combined Statements of Operations and Changes in Net Assets and require additional disclosures.

(2) Losses on the Provision of Uncompensated Care-

In accordance with its mission and purpose, the Medical Center maintains a policy of accepting all patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, the Medical Center accepts patients from outside the primary service area regardless of their ability to pay. The Medical Center defines indigent patient care as services rendered to patients whose families' annual income or net worth falls below certain minimum standards. As such, losses absorbed by the Medical Center in rendering services to patients who are covered under governmental programs which are designed to aid low income families (primarily the Medicaid program) are considered indigent patient care.

The following information summarizes uncompensated care provided during the years ended June 30, 2011 and 2010:

2011			
CHARGES	Hospital	Physician	Total
Charges under Medicaid and other entitlement programs	\$856,494	\$227,182	\$ 1,083,676
Charity care not eligible for Medicaid assistance, at established charges	29,958	1,046	31,004
Other uncollectible self pay, at established charges	49,532	6,625	56,157
Total Medicaid, charity care and other uncollectible self pay charges	\$935,984	\$234,853	\$1,170,837
COSTS/LOSSES			
Estimated costs to provide uncompensated care	\$474,986	\$161,343	\$636,329
Reimbursement from Medicaid programs	(284,671)	(33,429)	(318,100)
Losses on the provision of uncompensated care	(190,315)	(127,914)	(318,229)
Funds received from HCAP and tax levy	18,065	-	18,065
Losses on provision of uncompensated care net of HCAP and tax levy	\$(172,250)	\$(127,914)	\$(300,164)

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

2010			
CHARGES	Hospital	Physician	Total
Charges under Medicaid and other entitlement	\$7.67.060	Φ202.000	Ф. 070.057
programs	\$767,968	\$202,089	\$ 970,057
Charity care not eligible for Medicaid			
assistance, at established charges	26,225	3,304	29,529
Other uncollectible self pay, at established			
charges	42,796	8,690	51,486
Total Medicaid, charity care and other uncollectible self pay charges	\$836,989	\$214,083	\$1,051,072
emonitore son puly emuges			
COSTS/LOSSES			
Estimated costs to provide uncompensated care	\$411,720	\$114,963	\$526,683
Reimbursement from Medicaid programs	(287,500)	(29,649)	(317,149)
Losses on the provision of uncompensated care	(124,220)	(85,314)	(209,534)
Funds received from HCAP and tax levy	16,348		16,348
Losses on provision of uncompensated care net of HCAP and tax levy	\$(107,872)	\$(85,314)	\$(193,186)

The cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from the 2010 and 2009, cost reports, respectively, as the 2011 cost report is not yet available. Management does not believe that the difference in the cost report year would have a material impact on the amounts calculated.

(3) Tax Levy Funds-

Under an agreement with Hamilton County, Ohio (the County), the Medical Center receives tax-supported funding from the County to reimburse the Medical Center for the provision of charity care to the County's indigent residents. During fiscal 2011 and 2010, the Medical Center recognized \$6,000, respectively, of tax levy reimbursement in the accompanying Combined Statements of Operations and Changes in Net Assets.

The current tax levy agreement covers the period of the approved five year tax levy renewal, January 1, 2007 through December 31, 2011, which is subject to renewal by the voters of Hamilton County, Ohio. In each of the years 2007-2011, the County is scheduled to distribute \$6,000 to the Medical Center, subject to appropriation by the Board of County Commissioners. The amount distributed by the County from the Tax Levy proceeds to the Medical Center during each year of the Term hereof is subject to an annual appropriation at the discretion of the Board of County Commissioners. On an annual basis, the Medical Center shall render hospital inpatient and outpatient health and hospitalization services to medically indigent Hamilton County residents who are "Eligible Individuals" that have a total cost of at least the amount of the annual payments distributed to the Hospital under this Agreement for that year.

The vote on the next tax levy five year renewal will be held in November 2011. The Hamilton County Commissioners are recommending that the Medical Center portion of the tax levy, if passed by voters, will approximately \$5,200 annually.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(4) Funds in Trust-

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

	June 30,	
	2011	2010
Self-insurance funds-		_
Professional liability	\$ 162	\$ 973
Employee health and workers' compensation	436	468
Bond principal and interest escrow funds	4,008	3,991
Tomorrow Fund	14	97
Escrow Fund	-	40
	\$4,620	\$5,569

(a) <u>Self-Insurance Funds</u>--Cincinnati Children's has established an irrevocable trust fund for the payment of professional liability claim settlements. See Note 6 for further discussion of professional liability self-insurance.

Cincinnati Children's has also established a trust fund for the payment of claims related to certain self-insured employee health care programs.

(5) Property and Equipment-

Property and equipment consists of the following:

	June 3	30,
	2011	2010
Land	\$ 31,525	\$ 30,473
Land improvements	17,302	16,528
Buildings and building improvements	989,868	923,495
Equipment	538,178	573,273
Construction in progress	6,032	24,096
	1,582,905	1,567,865
Accumulated depreciation	(731,204)	(721,736)
Property and equipment, net	\$ 851,701	\$ 846,129

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(6) <u>Professional Liability</u>-

October 1, 1991

The Medical Center is self-insured for losses from professional and patient general liability.

\$2,000

The following details the amounts the Medical Center has purchased for excess coverage and the limits by period:

For claims made subsequent to:

June 1, 2008	\$10,000 (\$25,000 in aggregate)
October 1, 2004	\$10,000 (\$20,000 in aggregate)
October 1, 2002	\$4,000 (\$14,000 in aggregate)
October 1, 2001	\$3,000

Coverage under this insurance policy was limited to \$35,000 per occurrence and in the aggregate for each of the policy years ended September 30, 1997. This coverage was increased to \$50,000 for the policy years through September 30, 1998 and after. This coverage was increased to \$60,000 for the policy years ending May 31, 2008 and after. The Medical Center has also purchased excess liability coverage on a claims made basis in order to increase the annual aggregate coverage to an amount not to exceed \$75,000, when combined with the occurrence basis policy discussed above. Effective October 1, 2000, the Medical Center purchased coverage from River City for claims against employed physicians, which is subject to the same limits discussed above.

The actuarial present value of expected professional and patient general liability self-insurance costs (including incurred, but not reported claims) of \$21,675 and \$15,231 for 2011 and 2010, respectively, has been accrued in the accompanying Combined Balance Sheets. Accrued professional and general liability losses have been discounted at a rate of approximately 4% at June 30, 2011 and 2010, respectively. The costs of professional and patient general liability self-insurance, including premiums paid for stop-loss coverage, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Combined Statements of Operations and Changes in Net Assets. On an ongoing basis, management reviews the status of potential claims and incidents, as well as legal proceedings, and, based upon consultation with a professional actuary, adjusts the accrued losses and self-insurance funding levels to reflect its best estimate of the present value of expected professional and patient general liability self-insurance costs. Professional and patient general liability expense amounted to \$17,686 and \$11,748 for fiscal 2011 and 2010, respectively.

The Medical Center is the subject of or a party to various litigation, including professional and patient general liability, which involves routine matters incident to the course of business. Management does not believe any current proceedings will have a material adverse effect on its combined financial position or results of operations.

(7) Capital Lease Obligations-

The Medical Center leases certain equipment under capital leases. During fiscal 2011, Cincinnati Children's entered into certain lease agreements for equipment with an asset value of approximately \$4,898. During fiscal 2010, Cincinnati Children's entered into certain lease agreements for equipment with an asset value

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

of approximately \$1,389. The aggregate future minimum lease payments total \$4,993, with \$1,342 due in fiscal 2012.

(8) Bonds Payable and Notes Payable-

Bonds payable and notes payable for the years ended June 30, 2011 and 2010 consist of the following:

	2011	2010
Bonds payable and notes payable:		
Series 1993, 5.0% due through 2013, net of unamortized		
discount of \$29 in 2011 and \$56 in 2010	\$ 3,671	\$ 5,364
Series 1997, variable interest (0.09% at June 30, 2011), due		
through 2017	32,485	33,760
Series 1998, 4.75% to 5.375% due through 2028, net of		
unamortized discount of \$2,984 in 2011 and \$3,123 in 2010	110,541	114,572
Series 2000, variable interest (0.09% at June 30, 2011), due		
through 2028	49,080	49,550
Series 2002, variable interest (0.09% at June 30, 2011), due		
Through 2028	22,625	23,570
Series 2004, 4.00% to 5.50% due through 2034, net of		
unamortized discount of \$62 in 2011 and \$2 in 2010	85,448	87,488
Series 2006K, 4.25% to 5.00%, due through 2032, net of		
unamortized premium of \$422 in 2011 and \$432 in 2010	63,497	63,507
Series 2007M, variable interest (0.07% due at June 30,		
2011), due through 2037	30,615	30,615
Series 2007N, variable interest refinanced November 2010	-	30,615
Series 2008, variable interest (0.25% due at June 30, 2011),		
due through 2036	19,047	19,045
Series 2009, 4.20% due through 2019	24,000	27,000
Series 2010, 2.27% due through 2020	27,000	-
Note Payable on Vernon Manor Property, interest at 4.90%	28,200	-
IBM Credit LLC, 6.17% interest, paid in full November 2010	-	722
Total bonds payable and notes payable	496,209	485,808
Less- current portion	(18,090)	(14,282)
Bonds payable and notes payable - long-term	\$478,119	\$471,526

(a) Bonds Payable—The Medical Center has pledged their gross revenues, as defined, to secure the payment of Series 1993, 1997, 1998, 2000, 2002, 2004, 2006, 2007, 2008, 2009 and 2010 bonds. The Medical Center is bound by certain financial covenants included in the bond indentures, letters of credit (fully securing the 1997, 2000, 2002, 2007 and 2008 issuances) and related agreements. Among other restrictions is a requirement to maintain a minimum Debt Service Coverage Ratio, as defined. The Medical Center is in compliance with its debt covenants as of June 30, 2011 and 2010.

Payment of the principal of, and the interest on, the Series 1993, 1998, 2004 and 2006 bonds is insured by a policy of municipal bond insurance. The 1997, 2000, 2002, 2007 and 2008 bonds may be tendered to a remarketing agent by bondholders on business days for full payment of principal and accrued interest. The Medical Center has entered into standby letters of credit that commits major banks to make funds available to purchase the bonds that are not remarketed. The Medical Center is

Combined Financial Statements

For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

required to maintain these or similar agreements until the bonds have been paid or converted to fixed rate obligations.

The interest rates on the 1997, 2000, 2002, 2007 and 2008 variable rate bonds are reset weekly by a rate-setting agent.

(b) Future Debt Maturities --

The following is a schedule of future debt maturities:

2012	\$ 18,090
2013	18,563
2014	19,152
2015	19,735
2016	20,314
Thereafter	403,006
	\$498,860

- (c) <u>Line of Credit</u> -- In August 2008, Cincinnati Children's secured a \$40,000 line of credit. The line of credit expires in February 2012 and bears interest at the monthly LIBOR rate plus 100 basis points. There were no draws on the line of credit during fiscal 2011 or 2010.
- (d) Note Payable on Vernon Manor Property -- Cincinnati Children's entered into an agreement with a Developer to renovate and occupy the Vernon Manor property to be used primarily for administrative office space. The property is located near the main campus. Additionally, a parking garage was constructed on adjacent property in order to provide parking for the occupants of the building. As part of the agreement, Cincinnati Children's agreed to make fixed monthly payments over the seventeen year term of the agreement. The present value of such fixed payments at June 30, 2011 is \$28,200 using Cincinnati Children's estimated tax-exempt interest rate at the time of the agreement of 4.90%. The agreement also calls for variable payments monthly to cover operating expenses for the office building and the parking garage. Cincinnati Children's took occupancy of the facility on June 27, 2011. Additionally, the agreement has a provision that Cincinnati Children's can purchase the facility at the end of the seven years for the then fair market value. As part of the transaction, Children's recorded non-cash transactions for the acquisition of the property of \$30,000 and assumption of notes payable and deferred costs of \$30,000.
- (e) <u>Subsequent Event</u> Subsequent to year-end, Cincinnati Children's refinanced \$62,135 of the outstanding 1998G bonds with tax-exempt direct bank placement obligations. The obligations bear interest at a fixed rate of interest of 2.207%. The obligations mature in fiscal 2019.

(9) Employee Benefit Plans-

The Medical Center maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. The Medical Center's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

The Medical Center's investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with our desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. The portfolio's target asset allocation is 60 percent equities, 35 percent fixed income and 5 percent Real Estate Investment Trusts

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

with specified allowable ranges around these targets, plus or minus 10 percent based on the manager's discretion. Within the equity market, the investments are broadly diversified among various industry sectors in the domestic market. Within the debt segment, the investments are diversified between U.S. government bonds, Government Agency bonds and Corporate bonds. Investment risk is measured and monitored on an ongoing basis through regular reports from the investment managers.

The Medical Center's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2011 and 2010 by asset category is as follows:

	2011	2010
Equity common collective trust		_
funds	49.1%	45.1%
Bond mutual funds and common		
collective trust funds	34%	39.8%
International equity common		
collective trust fund	12.2%	10.5%
Real estate common collective		
trust fund	4.5%	4.3%
Cash and cash equivalents	0.2%	0.3%

At June 30, 2011 the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows:

•	<u>Level 1</u>	Level 2	Level 3
Money Market mutual funds	\$ 688	\$ -	\$ -
Bond mutual funds	74,155	-	-
Bond common collective trust funds	-	88,091	-
Equity common collective trust funds	-	234,274	-
International equity common collective			
trust fund	-	58,283	-
Real estate common collective trust fund	-	21,512	-
	\$74,843	\$402,160	\$ -

At June 30, 2010 the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows:

	Level 1	<u>Level 2</u>	Level 3
Money Market mutual funds	\$ 1,022	\$ -	\$ -
Bond mutual funds	54,208	-	-
Bond common collective trust funds	-	77,849	-
Equity common collective trust funds	-	149,814	-
International equity common collective			
trust fund	-	34,812	-
Real estate common collective trust fund	-	14,316	-
	\$55,230	\$276,791	\$ -

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The following table reflects the weighted average assumptions utilized to determine benefit obligations were:

	2011	2010
Discount rate used to determine actuarial present value of the		
projected benefit obligation	5.76%	5.51%
Assumed rate of increase in compensation levels	4.00%	4.00%

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Combined Balance Sheets as of June 30, 2011 and 2010, utilizing actuarial measurement dates as of June 30, 2011 and 2010.

30, 2011 and 2010.	2011	2010
Change in projected benefit obligation:		
Projected benefit obligation at beginning of year	\$607,864	\$471,598
Service cost	32,068	24,448
Interest cost	33,205	29,078
Other actuarial losses	12,201	88,192
Benefits paid	(6,575)	(5,452)
Projected benefit obligation at end of year	678,763	607,864
Change in plan assets:		
Fair value of plan assets at beginning of year	332,022	232,096
Actual return on plan assets	82,156	40,548
Employer contributions	69,400	64,830
Benefits paid	(6,575)	(5,452)
Fair value of plan assets at end of year	477,003	332,022
Funded status	(201,760)	(275,842)
Net accrued pension liability in Combined Balance Sheets	\$(201,760)	\$(275,842)

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

	2011	2010
Net actuarial loss	\$273,777	\$340,248
Net prior service cost	580	1,123
	\$274,357	\$341,371

The estimated actuarial loss and prior service cost that will be amortized from Unrestricted Net Assets into net pension cost in fiscal 2012 are \$18,474 and \$543, respectively.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

	2011	2010
Discount rate used to determine actuarial present value of the		
projected benefit obligation	5.51%	6.22%
Assumed rate of increase in compensation levels	4.00%	4.00%
Expected long-term rate of return on plan assets	8.00%	8.00%

The Medical Center's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Net periodic pension cost for 2011 and 2010 related to the defined benefit plan consisted of the following components:

	2011	2010
Service cost	\$32,068	\$24,449
Interest cost	33,205	29,078
Return on plan assets	(30,607)	(26,147)
Amortization of prior service cost	543	543
Recognized net actuarial loss	27,122	18,076
Net periodic pension cost	\$62,331	\$45,999

Based on preliminary estimates, we expect fiscal 2012 contributions of approximately \$72,900 for the qualified defined benefit plan.

The accumulated benefit obligation for the pension plan was \$566,222 and \$518,445 at June 30, 2011 and 2010, respectively.

The Medical Center's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

2012	\$12,983
2013	16,081
2014	19,023
2015	22,228
2016	25,908
2017-2021	196,982

All other retirement plans maintained by the Medical Center are defined contribution plans. The Medical Center's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense related to these other plans was approximately \$16,749 and \$15,814 in fiscal 2011 and 2010, respectively. The Medical Center maintains a matching contribution related to non-faculty, non-senior management employees in which the Medical Center will contribute one dollar for every dollar an employee contributes to a 403(b) plan up to 1% of an employees salary subject to certain restrictions, including a three year vesting schedule and employee contributions made each pay period. The total amount expensed in fiscal 2011 and 2010 related to this plan was approximately \$3,225 and \$2,722, respectively.

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The Medical Center has a nonqualified deferred compensation plan, which permits eligible officers, directors and key employees to defer a portion of their compensation. The deferred compensation amounts are in participant directed investments and are considered trading securities. The participants have the option of deferring the amounts for no less than two years, but no greater than retirement age. If a participant chooses to defer amounts to less than retirement age they have one option to extend the deferral term or to be paid out the fair value of the assets, net of taxes upon expiration. The amounts are at a substantial risk of forfeiture and will revert back to the Medical Center if the employee violates his noncompete agreement. The fair value of the assets and liability to participants included in the accompanying balance sheets were \$9,384 and \$8,081 at June 30, 2011 and 2010, respectively. The amount of deferred compensation expense recognized in fiscal 2011 and 2010 was \$12 and \$1,102, respectively. Additionally, the Medical Center provides for individual nonqualified deferred compensation benefits for retention of key employees with varying terms. The fair value of the assets and liability to participants related to these individual agreements in the accompanying combined balance sheets were \$4,738 and \$6,666, respectively at June 30, 2011 and 2010.

In addition to providing pension benefits, the Medical Center makes available medical and dental benefits for certain eligible employees upon retirement from the Medical Center at cost. Substantially all employees may become eligible for such benefits upon retiring from active employment of the Medical Center. Former employees who retired prior to March 1, 1997 are entitled to subsidized medical and dental benefits.

The postretirement benefit obligations as of June 30, 2011 and 2010 were as follows:

2011	2010
\$8,421	\$8,262
373	471
631	512
135	106
(202)	177
(1,450)	(1,107)
\$7,908	\$8,421
	\$8,421 373 631 135 (202) (1,450)

Amounts included in Unrestricted Net Assets but not yet recognized in postretirement cost consist of:

	2011	2010
Net actuarial loss	\$3,399	\$ 3,949
Net prior service cost	(1,168)	(1,453)
	\$2,231	\$2,496

The estimated actuarial loss and prior service cost that will be amortized from Unrestricted Net Assets into net postretirement cost in fiscal 2012 are \$305 and \$(285), respectively.

Combined Financial Statements
For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

The above table reflects the following weighted average assumptions to determine postretirement obligations:

	2011	2010
Discount rate	4.49%	4.63%
Health care cost trend rate declining gradually to 5% through		
2019 and beyond, respectively	8.50%	9%

Net periodic cost for 2011 and 2010 related to the medical and dental postretirement benefits consisted of the following components:

	2011	2010
Interest cost	\$373	\$471
Amortization of unrecognized net gain and prior service credit	64	68
	\$437	\$539

For fiscal 2011 and fiscal 2010, the discount rate used to determine the net periodic postretirement costs was 4.63% and 5.97%, respectively.

Assumed healthcare cost trend rates have a significant effect on the amounts reported for healthcare plans. A one-percentage-point change in assumed healthcare cost trend rates would have the following effects:

	1-Percentage-	1-Percentage-
	Point	Point
	<u>Increase</u>	Decrease
Effect on total of service and interest cost components	\$ 28	\$ (25)
Effect on accumulated postretirement benefit obligation	540	(488)

The Medical Center expects to make the future benefit payments, which reflect expected future service, as appropriate. The Medical Center expects to receive future subsidies under Medicare Part D. The following benefit payments and subsidies are expected to be paid (or received) over each of the next five years and thereafter.

	Payments	Subsidies
2012	\$ 718	\$116
2013	733	118
2014	741	119
2015	742	118
2016	734	116
2017-2021	3,297	517

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(10) Commitments and Contingencies-

- (a) <u>Laws and Regulations</u>—The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as license, accreditation, privacy, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Management believes that the Medical Center is in compliance with all fraud and abuse as well as other applicable government laws and regulations. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.
- (b) <u>Capital Commitments</u>--The Medical Center has entered into agreements with general contractors for several renovation projects and information system technology projects. The Medical Center has committed to spend an additional approximately \$4,823 in connection with current active projects as of June 30, 2011. The projects are expected to be completed in fiscal 2012.
- (c) <u>Funding Commitment</u> -- During fiscal 2005, the Board of Trustees of Cincinnati Children's approved a revocable commitment for up to \$15,000 non-recourse loan over seven years to Uptown Consortium Inc. These funds are to be used to invest in commercial and residential projects in the uptown area. As of June 30, 2011, Cincinnati Children's has provided \$12,867 of funding in relation to this commitment.
 - As part of fee assignment agreements with physician employees, the Medical Center has agreed to fund expenditures of \$199,125 and \$179,605 as of June 30, 2011 and June 30, 2010, respectively, in those physicians' respective departments at the Medical Center as requested by those departments.
- (d) <u>Investment Commitment</u> -- Cincinnati Children's has made commitments to invest \$12,000 in two limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology and advanced manufacturing. As of June 30, 2011, Cincinnati Children's had funded \$8,504 of this commitment.
- (e) <u>Operating Leases</u> Cincinnati Children's leases certain property for varying periods. Future minimum rental commitments under non-cancellable operating leases are as follows:

FY 2012	\$3,730
FY 2013	2,406
FY 2014	1,488
FY 2015	539
FY 2016	495
Thereafter	1,439

Combined Financial Statements For the Years Ended June 30, 2011 and 2010, respectively (dollars in thousands)

(11) Functional Expenses-

The functional expenses of the Medical Center are as follows:

	2011	2010
Patient services	\$1,060,880	\$1,050,126
Research and education	369,698	296,228
Support services	208,187	193,084
	\$1,638,765	\$1,539,438

(12) Fair Value of Financial Instruments-

The following methods and assumptions were used by the Medical Center in estimating its fair value disclosures for financial instruments:

<u>Cash and Cash Equivalents</u>--The carrying amounts reported in the Combined Balance Sheets approximate fair value.

<u>Accounts Receivable and Accounts Payable and Accrued Expenses</u> -- The carrying amounts reported in the Combined Balance Sheets approximate fair value because of the relative short maturity of these items.

<u>Marketable Securities and Assets Limited As To Use</u>--The carrying amounts reported in the Combined Balance Sheets approximate fair value. Fair value is determined by the trustee holding the assets based on published market prices.

<u>Bonds Payable and Notes Payable</u>--The fair values of the Medical Center's bonds payable and notes payable are estimated by the bond trustee based on current rates for debt with similar remaining maturities. The fair value of the bonds payable at June 30, 2011 and 2010 was \$485,357 and \$471,390, respectively.

(13) Subsequent Events

Management reviewed subsequent events through October 25, 2011, the date the financial statements were issued, noting no changes were required to the financial statements or footnotes, except in relation to footnotes 1(a) and 8(e) contained herein.

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2011

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
Department of Defens∈	Military Construction, National Guard	Epi Survey of Iowa Ammunition Plant Worker:	University of Iowa	Military Construction, National Guard Total	W911SR05C0055	12.400	-	\$25,341.20 25,341.20	\$25,341.20 25,341.20
	Military Medical Research and Developmer	Development of Strategies to Treat and Prevent Noroviru Therapeutic Targets for Neurofibromatosis: Identificat Neurofibromatosis Consortium (STOPN Tuberrous Scierosis Complex Natural History Stud	University of Alabama-Birminghan	Massachusetts General Hospita	W81XWH0410066 W81XWH0410273 W81XWH0510615 W81XWH0610538	12.420 12.420 12.420 12.420	(2,294.20)	558,688.23 - 151,058.31 105,696.29	558,688.23 (2,294.20) 151,058.31 105,696.29
		Early Prediction Of Lupus Nephritis Using Advanced Prot Therapeutic Targets for Peripheral Nerve Tumor		House Ear Institute Massachusetts General Hospita	W81XWH0710322 W81XWH0910135	12.420 12.420	42,376.06 30,958.62	(1,608.57) 99,546.65	(1,608.57) 172,881.33
		Role of Foxmt in the Pathogenesis of Prostate Cance Next Generation DNMT-1 Depletion Therapy for Leukemi Modelling Brain Defects in NFT Genetic Studies of Food Allergies Research Prograt Molecular Signatures of Cancer Metastatsic PRO094002 - 'Cenome-Wide Assoc. Study in African-Arr Genetic & Epigenetic Diffencese in Monozygotic Twins w Identification and Study of Novel Genes Critical to Sur Gap Junction Intercellular Communication in Bone Marro Regulation and Function of TIFAB in Myelodysplastic Syn	Cleveland Clinic	Military Medical Research and Development T	W81XWH0910389 W81XWH0910671 W81XWH1010116 W81XWH1010167 W81XWH1010325 W81XWH1010867 W81XWH1110144 W81XWH1110296 W81XWH1110468 otal	12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420 12.420	71,040.48	121,820.77 182,673.15 282,672.48 313,031.33 154,050.22 390,589.06 67,435.38 5,063.06 31,539.39 1,247.20 2,463,502.95	121,820,77 182,673.15 282,672.48 313,031.33 154,050.22 390,589.06 67,435.38 5,063.06 31,539.39 1,247.20 2,534,543.43
				Department of Defense Total			71,040.48	2,488,844.15	2,559,884.63
Department of Education	Education Research, Development and Disseminatio	Organizational Skills Interventions for Children with Al		Education Research, Development and Disser	R305A090305 nination Total	84.305	-	147,279.12 147,279.12	147,279.12 147,279.12
	National Institute on Disability and Rehabilitation Researc	Rehabilitation Research and training Center for Trauma		Case Western Reserve University Nationwide Childrens Hospita The Children's Hospital Associatior University of Oregon	H133B090010	84.133	55,516.55 92,319.69 21,147.96 134,555.18	428,096.81	731,636.19
		Teen Online Problem Solving for Pediatric Brain Injur Web Therapy to Improve Outcomes after Traumatic Brain I			H133G050239 H133G060167	84.133 84.133	,,,,,,	(5,659.60) (8,540.97)	(5,659.60) (8,540.97)
		web Therapy to improve Outcomes after Traumatic Brain 1		National Institute on Disability and Rehabilitat	ion Research Tota	04.133	303,539.38	413,896.24	717,435.62
	Special Education-Grants for Infants and Familie	Child Find		Special Education-Grants for Infants and Fam	03130011HB0310 ilies Tota	84.181	-	45,461.39 45,461.39	45,461.39 45,461.39
	Special Education Tech. & Media Srvcs for Individuals w/ Disabilitie	Influencing Outcomes for Children Who Are Deaf-Bline	The Teaching Res Instit of W Oregon Univ		H327A080045A	84.327		49,048.99	49,048.99
				Special Education_Technology and Media Ser Individuals with Disabilities Tota	vices for	,	-	49,048.99	49,048.99
				Department of Education Total			303,539.38	655,685.74	959,225.12
Department of Justice	Crime Victim Assistance	Victims Assistance Funds	Crime Victims Assistance Office	Crime Victim Assistance Total	2010VADSCE483	16.575	-	52,383.45 52,383.45	52,383.45 52,383.45
	Missing Children's Assistance	Program Support Grant NC#	National Children's Alliance	Missing Children's Assistance Total	6-CINC-OH-SA10	16.543	-	9,906.00 9,906.00	9,906.00 9,906.00
				Department of Justice Total			-	62,289.45	62,289.45
Department of Transportation	State and Community Highway Safet	Occupant Protection Region Coordinate Teen Resraint		State and Community Highway Safety Total	DOH01-0000015571 GG20113100000052000	20.600 20.600	-	40,337.74 6,728.91 47,066.65	40,337.74 6,728.91 47,066.65
				Department of Transportation Total		•	-	47,066.65	47,066.65
National Science Foundation	Biological Sciences	Probing the robustness of a developmental system			IOS-0843424	47.074		259,733.20	259,733.20
	Mathematical and Physical Science:	Extension of Censored Quantile and Empirical Likelihoc		Biological Sciences Total	NSF 1007666	47.049	-	259,733.20 24.416.66	259,733.20 24.416.66
	Wathernatical and Friysteal octorice.	Extension of Censored Quantile and Empirical Extension		Mathematical and Physical Sciences Total	1431 1007000	47.043		24,416.66	24,416.66
				National Science Foundation Total			-	284,149.86	284,149.86
Department of Labo	Comp. Grants for Workers Training & Placement in High Growth	Health Careers Collaborative of Greater Cincinna			GCJ200701060A39	17.275		79,647.35	79,647.35
	Emerging Industry Sectors			Competitive Grants for Workers Training and High Growth and Emerging Industry Sectors 1		•	-	79,647.35	79,647.35
				Department of Labor Total			-	79,647.35	79,647.35
Dept of Health and Human Serv	Aging Research	CALERIE Phase II Mechanisms of age-related inflammatory response in hemi	Duke University	Aging Research Total	AG022132 AG027990	93.866 93.866	-	13,612.13 312,971.18 326,583.31	13,612.13 312,971.18 326,583.31
	Allergy, Immunology and Transplantation Researc	Analysis of Staphylococcus Aureus Host Interaction:	Texas A & M		AI020624	93.855		37,422.44	37,422.44
		Genetic Linkage in Lupus Long-Term Immunity Against Toxoplasmosi	George Washington University		AI024717 AI033325	93.855 93.855		436,402.77 75,238.20	436,402.77 75,238.20
		Regulations of Gastroinestinal Eosinophil Norovirus and their receptors CD40 Ligand Dysregulation and HIV Pathogenesis	J	University of Cincinnati	AI045898 AI055649 AI056927	93.855 93.855 93.855	6,224.99	425,247.98 302,210.06 (19,210.02)	425,247.98 308,435.05 (19,210.02)

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
		Regulation of Apoptosis in Activated Primary T Cell		St Jude Children's Research Hospita	AI057753	93.855	11,864.27	198,848.38	210,712.65
		Molecular Regulation of Immune Complex Diseas			AI059305	93.855		21,423.14	21,423.14
		Immunology/Allergy Fellowship Training Grant T3	University of Cincinnat		AI060515	93.855		54,964.13	54,964.13
		Rapid Trichomonas Tests: A Teen STI Prevention Strateg			AI063182	93.855		(18,333.90)	(18,333.90)
		Immunobiology of Paenut Allergy and its Treatment: A PI	Mount Sinai Medical Center		AI066738	93.855		152,247.21	152,247.21
		HLA/KIR Region Genetics in Pediatric Arthriti:		Childrens Hosp Oakland BACPAC Resources	AI067150	93.855	28,056.00	76,490.22	104,546.22
		Transforming Growth Factor beta in T-Cell Homeostasis a	University of Arizona		AI067903	93.855		24,133.63	24,133.63
		Role of Regulatory T Cells in HIV Infectior		University of Cincinnati	AI068524	93.855	19,183.68	201,021.22	220,204.90
		Epithelial Genes In Allergic Inflammatio			AI070235	93.855		916,767.65	916,767.65
		IGG Isotype Regulation of Antibody-Mediated Disorder	University of Cincinnat		AI072040	93.855		103,984.94	103,984.94
		Interleukin-9 in Experimental Intestinal Anaphylaxi			AI073553	93.855		443,472.16	443,472.16
		Behavioral and Virologic Impact of HPV Immunizatio		Indiana University	AI073713	93.855	74,950.87	448,073.05	533,625.80
				Columbia University			10,601.88		
		Functional Analysis of NK cells and their potential to			AI074743	93.855		346,962.96	346,962.96
		Control of Immune responses by lipoxins during tubercu			AI075038	93.855		313,971.75	313,971.75
		Regulation of TLR Signaling and Innate Immunity by RP10			AI075159	93.855		346,104.98	346,104.98
		Novel Broad Spectrum Therapeutic Glycans Against Catego	Boston College		AI075563	93.855		58,335.82	58,335.82
		HPV Vaccination, Attitudes and Suquential Behaviors In	Indiana University		AI079090	93.855		9,547.29	9,547.29
		Role of Acidic Environment in Eosinophilic Inflammatio			AI079251	93.855		207,789.19	207,789.19
		T cell memory to cell-associated antigens by a new D			AI079545	93.855		(14,034.63)	(14,034.63)
		Functional Identification of Genes Mutated in FHLI			AI079759	93.855		143,881.74	143,881.74
		Investigations into XIAP-deficient X-linked Lymphoprol			AI079797	93.855		69,318.87	69,318.87
		Activated Protein C for Treatment of Radiation Combine	Blood Center of Wisconsin, Inc		AI080556	93.855		93,060.17	93,060.17
		Neuronal Regulation of HSV Lytic and Latent Infectio			AI081083	93.855		135,171.45	135,171.45
		Novel Immune-based therapy for Leishmaniasis and T	NewLink Genetics Corporation		AI082812	93.855		96,325.28	96,325.28
		Epithelial Regulation of Th2 Immune Responses in the Lu			AI083315	93.855		346,859.61	346,859.61
		IL-13 Associated Eosinophil Lung Response:			AI083450 AI084414	93.855 93.855		351,045.78	351,045.78
		Biology of IL-13 Receptor Alpha-2 in Asthm:	Children I Hannital Banton		AI084414 AI087628	93.855		95,219.86 98.633.11	95,219.86 98.633.11
		Gene Therapy for SCID-X1 Using Self-Inactivating Gammar	Children's Hospital Bostor		AI087628 AI088116	93.855		693,817,39	693.817.39
		Explaining Racial Disparities in Child Asthma Morbidit		Habitania of laura	AI088372	93.855	184.843.42		484.026.61
		Allergenicity resulting from functional mimicry of the Role of Acidity and GPR65 in Food Allerg		University of Iowa	AI088559	93.855	104,043.42	299,183.19 158.306.36	158.306.36
		Receptor Mimics for Rapid Detection, Typing, and Suscer	University of Cincinnat		AI088559 AI089450	93.855		21.731.75	21.731.75
		Novel Vaccine Against Norovirus	University of Ciricinnat	Ligocyte Pharmaceutical, Inc	AI089430 AI089634	93.855	215,771,75	325,598,92	807.424.67
		Novel vaccine Against Norovirus		Virginia Tech	A1089634	93.833	266,054.00	323,398.92	807,424.67
		Regulation of TH2 memory/effector cells during allerg		Vilginia recii	AI090129	93.855	200,034.00	304.756.55	304.756.55
		Structure-Function Relationship of the Adenovirus Assem			AI090309	93.855		37.015.76	37.015.76
		Norovirus P Particle, A Multifunctional Platform For Va			Al092434	93.855		1,136.41	1.136.41
		Role of Spi-C in eosinophil development and functional			Al093673	93.855		26.013.35	26.013.35
		root of opi o in coomopiii dovelopnon and renoitoria		Allergy, Immunology and Transplantation Re		00.000	817,550.86	8,446,156.17	9,263,707.03
ADDA	A ARRA Accelerating Adoption of Comparative Effectivenes	Bundling Effective Resident Handoff Practices to Improv	Children's Hospital Bostor		AE00029	93,726		43.680.63	43.680.63
	Research (CER)	Building Effective Nesident Handon Fractices to Improv	Children's Flospital Bostol	ARRA Accelerating Adoption of Comparative		33.720		40,000.00	45,000.05
	Nessearch (CEN)			Effectiveness Research (CER) Total			•	43,680.63	43,680.63
ARRA	ARRA - Emergency Medical Services for Children	Implementation of the PECARN Traumatic Brain Injury Pre			MC19289	93.418		17,827.30	17,827.30
				ARRA - Emergency Medical Services for Chil	dren Total		-	17,827.30	17,827.30
ARRA	ARRA - Prevention and Wellness - Leveraging National Organization	Evaluating Nat'l Efforts to Promote Community Tobacc	American Academy of Pediatric		AAP 696800	93.731		25,974.15	25,974.15
				ARRA - Prevention and Wellness - Leveraging Organizations Total	g Nationa		-	25,974.15	25,974.15

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Arthritis, Musculoskeletal and Skin Diseases Researc	Pediatric Rheumatology Training			AR007594	93.846		169,309.60	169,309.60
		HLA-B27 Misfolding an the UPR in Spondyloarthritis			AR046177	93.846	0.450.00	396,449.43	396,449.43
		Cincinnati Rheumatic Disease Core Cente		University of Cincinnati Arkansas Children's Hospita	AR047363 AR047784	93.846 93.846	6,450.93 4,410.00	561,792.58	568,243.51 1,194,509.48
		Multidisciplinary Clinical Research Cente		Children's Hospital of Philadelphia	ARU47784	93.846	2.184.99	1,071,260.38	1,194,509.46
				Children's Memorial Hospita			34,940.00		
				Children's Memorial Hospita Childrens National Medical Cente			34,940.00		
				Cleveland Clinic			23.371.68		
				Hackensack University Med. Cente			19.089.24		
				Medical University of South Carolina			3.000.00		
				North Shore L.I.J. Health System			5.925.00		
				Northwestern University			18,524.32		
				Phoenix Children's Hospita			3,315.00		
				University of Alabama-Birminghan			3,042.74		
				University of Chicago			2,446.13		
		Gene Expression in Pediatric Arthriti:			AR048929	93.846		35,260.66	35,260.66
		Program Project in the Genetics of SLEProject 2: Gen	University of Alabama-Birminghan		AR049084	93.846		14,308.64	14,308.64
		Early Agressive Therapy in JIA	Children's Hosp & Reg Med Ct-Seattle		AR049762	93.846		18,590.32	18,590.32
		A Randomized Clinical Trial in Juvenile Fibromyalg	11.1	University of Louisville	AR050028	93.846	7,948.05	22,788.48	30,736.53
		Bracing in Adolescent Idiopathic Scoliosi	University of Iowa		AR052113	93.846		10,575.79	10,575.79
		Role of IL-13 Receptors in Atopic Dermati			AR054490	93.846		319,119.96	319,119.96
		Longitudinal Determination of Outcomes of Adolescent: Efficacy Measures for Pediatric Lupus Studie:		Nationwide Childrens Hospita	AR054842 AR055054	93.846 93.846	6.570.00	382,028.83 94,427.20	382,028.83 140,516.69
		Efficacy ineasures for Fediatric Eupus Studie:		North Shore L.I.J. Health System	AK033034	93.040	9.677.25	54,427.20	140,516.09
				University of British Columbia			4.552.00		
				University of California			5.131.00		
				University of Chicago			5.154.24		
				University of Cincinnati			15,005.00		
		Joint Strong Intervention for Juvenile Arthriti	The University of Kansas Medical Ct		AR055183	93.846		15,240.00	15,240.00
		Neuromuscular Intervention Targeted to Mechanisms of AC		Boone County Board of Education	AR055563	93.846	10,457.46	387,370.35	428,796.29
				University of Kentucky			30,968.48		
		Multi-faceted approach to modeling ACL injury mechanism		University of Toledo	AR056259	93.846	273,513.74	41,155.19	314,668.93
		Behavioral Interventions & Long Term Outcomes in Juve			AR056687	93.846		110,723.65	110,723.65
		Use of Thermal and 3D Surface Imaging to Quantify Arth	Children's Hospital of Pittsburgh		AR056690	93.846		23,017.83	23,017.83
		A Developmentally-Based Tissue Engineering Approac	University of Cincinnat		AR056943	93.846		312,455.39	312,455.39
		Mechanisms linking the hemostatic protease thrombin			AR056990	93.846		274,941.79	274,941.79
		Genetics of Juvenile Idiopathic Arthritis and Subtype	Wake Forest University		AR057106	93.846		89,786.72	89,786.72
		Sex differences in ACL injury risk factors emerge durin		University of Cincinnat	AR057551 AR057940	93.846 93.846	9,077.77 8.188.72	64,831.97 385.917.44	73,909.74 394.106.16
		Enhancing PROMIS in Pediatric Pain, Rheumatology, and R Towards Measures of Lupus Nephritis Activity & Damage f		Children's Hospital of Philadelphia University of Cincinnat	AR059509	93.846	9,990.79	113,899.98	123,890.77
		Gfi-1 and Osteoblast Suppression in Multiple Myelom	University of Pittsburgh	Oniversity of Ciricinnat	AR059679	93.846	9,990.79	31.368.21	31.368.21
		On Faile Octobact cappiocolor in matter inycloni	Chivelenty of Financial	Arthritis. Musculoskeletal and Skin Diseases Re		00.010	525.934.53	4.946.620.39	5,472,554,92
				,			,	.,,	-,,
	Assistance Programs for Chronic Disease Prevention and Contri	SEARCH for Diabetes in Youth, Phase 3: Registry Study			DP002709	93.945		357,494.20	357,494.20
				Assistance Programs for Chronic Disease Prev	ention and	_			
				Control Total				357,494.20	357,494.20
	B. F. B. J. JB. J. T. J.	8.1.75			GM027673	00.050		40.584.67	40.584.67
	Biomedical Research and Research Training	Role of Eicosanoids in Shock Regulation of Wingless (Wg) Signaling and Morphoge	Medical University of South Carolina		GM027673 GM063891	93.859 93.859		264.363.89	264.363.89
		Genomic Analysis of Pediatric SIRS and Septic Shoc		Miami Children's Hospital	GM064619	93.859	(500.00)	128,061.30	127,561.30
		PPARgamma and PPARgamma agonists in septic shoc		Medical University of South Carolina	GM067202	93.859	47.805.26	257.128.33	304.933.59
		Optimization of Structures and Networks of Protein	The University of Texas at Austir		GM067823	93.859	47,000.E0	27.245.29	27.245.29
		Activities of the Bicoid Gradient in Drosophila Embryo	The onversity of result at rustin		GM072812	93.859		11,025.73	11,025.73
		Mechanisms of Endoderm Specification Along the A-P Axi			GM072915	93.859		180,452.56	180,452.56
		The Immunomodulatory Effects of Extracellular HSP 7			GM077432	93.859		81,819.96	81,819.96
		Hox Regulation of Sensory Organ Development in Drosoph			GM079428	93.859		258,982.28	258,982.28
		Alternative Macrophage Activation Limits Immunopatholog			GM083204	93.859		449,807.89	449,807.89
		Wnts interacting with Wnts: mechanism and biological si			GM084951	93.859		308,271.27	308,271.27
		Interferon - Mediated Reprogramming of Toll-Like Recep			GM085063	93.859		302,695.05	302,695.05
		Fundamental mechanisms of protein kinase activation loc			GM087374	93.859		269,245.51	269,245.51
		Roles of Retromer Complex in Developmer PPAR gamma in pediatric sepsis and the inflammatory res			GM087517 GM093135	93.859 93.859		227,304.99 162,038.10	227,304.99 162,038.10
		MMP-8 as a novel therapeutic target in sepsi			GM093135 GM096994	93.859		162,038.10 57.412.93	162,038.10 57.412.93
		mini -o as a novel inerapeutic target III sepsi		Biomedical Research and Research Training To		33.039	47,305.26	3,026,439.75	3,073,745.01
							,000.20	2,220,400.10	2,2.0,140.01

					Fadard Orant	т т			
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
Gov Agency	Blood Diseases and Resources Research	Comprehensive Sickle Cell Cente	Pass-Through Grantor		HI 070871	93.839	78.877.50	1.548.966.78	1.627.844.28
	blood biseases and Resources Research	Role of FA proteins in hematopoiesi			HL076712	93.839	70,077.30	411,892.84	411,892.84
		Stroke With Transfusions Changing To Hydroxyure:	St Jude's Children's Hospita		HL078787	93.839		(5,685.50)	(5,685.50)
		Molecular Mechanism of Severe Congenital Neutropeni	•		HL079574	93.839		77,133.49	77,133.49
		Role of Placenta Growth Factor in Sickle ACS			HL079916	93.839	664.02	87,803.91	88,467.93
		Molecular and Clinical Biology of VWI	Medical College of Wisconsir		HL081588	93.839		261.15	261.15
		Ohio Sickle Cell Alliance For Research	New England Research Institute:		HL083721	93.839	16,821.56	(8,695.12)	37,272.63
		Function and Regulation of FANCM in Fanconi Anemia		The Ohio State University	HL084082	93.839	29,146.19	360.148.41	360.148.41
		Hemostatic Factors as Determinants of Bacterial Virulen			HL085357	93.839		321,200.74	321,200.74
		Cell Type and Stimulus-Specific Signaling Role of CDC4			HL085362	93.839		314.892.56	314.892.56
		Mechanisms Linking Metastasis to Tumor Procoagulant an			HL085545	93.839		182,241.18	182,241.18
		FANCD2 Monoubiquitination in DNA Damage Response:		University of North Carolina-Chapel Hi	HL085587	93.839	7,331.66	354,023.18	361,354.84
		Rac GTPase Inhibition in Chronic Myelogenous Leukemi			HL087159	93.839		306,582.65	306,582.65
		Rac1 and Rac2 Guanosine Triphosphatases in Erythroi			HL088126	93.839		112,357.71	112,357.71
		An Animal Model of Hemophagocytic Lymphohistiocytosi			HL091769	93.839		345,174.10	345,174.10
		Training Program in Pediatric Hematologic and Oncolog			HL091805	93.839 93.839		135,693.67	135,693.67
		Thrombin-mediated proteolysis in neuroinflammato Development of Safe and Efficient Gene Therapy Strategi	Fred Hutchinson Cancer Research Cente		HL096126 HL098489	93.839		380,900.40 121,953.72	380,900.40 121,953.72
		TWITCH	St Jude's Children's Hospita		HL095647	93.839		50,642.02	50,642.02
		Fanconi Anemia as a Model for Susceptibility to Human P	Ot Gade a Grindren a Freedrich		HL108102	93.839		798.95	798.95
		· · · · · · · · · · · · · · · · · · ·		Blood Diseases and Resources Research Total			132,840.93	5,098,286.84	5,231,127.77
	Cancer Biology Research	Hypoxia and Potassium Channel Activity in T Lymphocyte	University of Cincinnat		CA095286	93.396		30,282.50	30,282.50
		Schwann Cells in Neurofibromatosis Type 2 (NF2			CA118032	93.396		305,751.01	305,751.01
		The Role of CBFb-MYH11 in Acute Myeloid Leukemi	0.1.1.0.1.		CA118319	93.396	5,357.00	233,212.57	238,569.57
		Antileukemic Effect of NK Cells in HCT for Pediatric AML Rac GTPases as Targets in Lymphomagenesi	St Jude's Children's Hospita		CA120583 CA125658	93.396 93.396		10,192.94 249,518.96	10,192.94 249,518.96
		Macrophages and Tumor Angiogenesi	Albert Einstein College of Medicine		CA123036 CA131270	93.396		189,829.23	189,829.23
		Activating robust immunity to tumor-associated antigen	Albeit Ellistelli Gollege di Medicili		CA138617	93.396		430,535.72	430,535.72
		Rac GTPase-Specific Small Molecular Inhibitor			CA141341	93.396	13,765.00	196,022.59	209,787.59
		Epigenetic manipulation of Leukemi		Cornell University	CA142601	93.396	22,000.00	290,983.43	312,983.43
		Role of Foxm1 in Lung Cancer Microenvironmer			CA142724	93.396		318,589.34	318,589.34
		Targeting Cdc42 in Leukemia Stem Cell			CA150547	93.396		293,800.48	293,800.48
		MicroRNA in Acute Myeloid Leukemia			CA159845	93.396		396.00	396.00
				Cancer Biology Research Total			41,122.00	2,549,114.77	2,590,236.77
	Cancer Cause and Prevention Research	Mechanisms of RET/PTC Rearrangement in Thyroid Cance	University of Pittsburgh		CA088041	93.393		11,292.25	11,292.25
	Carlor Cado and Frevention Resource	Fanconi Anemia and HPV Transformation	Onvoidity of Fittaburgh		CA102357	93.393		354,381.64	354.381.64
		Neurobehavioral Late Effects in Pediatric Brain Tumor	Baylor College of Medicine		CA112182	93.393		124,585.84	124,585.84
		A Molecular Basis for Neuroendocrine Carcinogenesi			CA112405	93.393		54,570.49	54,570.49
		Role and Regulation of the Human DEK Proto-Oncogen			CA116316	93.393		138,033.32	138,033.32
		Genetic Epidemiology of Osteosarcom	University of Minnesota		CA122371	93.393		11,962.01	11,962.01
		Sphinx: a new cause of hepatic neoplasi			CA133649	93.393	10 500 07	108,082.63	108,082.63
		Empirical Bayes Analysis of Quantile Regression Mode Mahabee-Gitten's Reduce Youth Smoking R0:			CA133944 CA142099	93.393 93.393	13,583.27	95,381.48 74,704.26	108,964.75 74,704.26
		The role of ATOH1 as a tumor supressor in colorectal ca			CA142099 CA142826	93.393		216.810.71	216.810.71
		The fole of ATOTT as a fullor supressor in colorectal ca		Cancer Cause and Prevention Research Total	OA142020	33.333	13,583.27	1,189,804.63	1,203,387.90
							,		
	Cancer Detection and Diagnosis Research	MR-Image Guided Focused Ultrasound for Treatment of Liv	Stanford University		CA121163	93.394		57,060.54	57,060.54
				Cancer Detection and Diagnosis Research Total			-	57,060.54	57,060.54
	Cancer Research Manpowe	Regulation of Cellular Growth and Differentiatio	University of Cincinnat		CA059268	93.398		47,464.67	47,464.67
	Cartor resocutor manpowe	The Ron Receptor Tyrosine Kinase In Hepatic Tumorigene:	Onvoidity of Ontonna.		CA111819	93.398		119,883.13	119,883.13
		Training Program in Cancer Therapeutic	University of Cincinnat		CA117846	93.398		52,743.96	52,743.96
		Improving Parent/Adolescent Communication about Tobacc	•		CA117864	93.398		111,506.91	111,506.91
		Molecular Pathogenesis of MLL-Fusion Gene Leukemi			CA122191	93.398		144,896.73	144,896.73
		Targeting Oncolytic HSV to Neuroblastoma and Malignant			CA132613	93.398		15,927.85	15,927.85
		The role of DEK in the differentiation-dependent HPV			CA138115	93.398 93.398		41,958.76 43.212.46	41,958.76 43,212.46
		The role of DEK in breast cancer development and therap		Cancer Research Manpower Total	CA139931	93.398		43,212.46 577,594.47	43,212.46 577,594.47
				Canco Mosearch manpower Total			-	311,334.41	311,334.41
	Cancer Treatment Research	Childhood Cancer Survivor Study	St Jude's Children's Hospita		CA055727	93.395		78,505.89	78,505.89
		The Pediatric Brain Tumor Consortiun	St Jude's Children's Hospita		CA081457	93.395		(107.68)	(107.68)
		COG Phase I Agreemen	National Childhood Cancer Foundation		CA097452	93.395		71,868.17	71,868.17
		Children's Oncology Group Chair Awara Oncolytic HSV Therapy in Immunocompetent Sarcoma Mode	National Childhood Cancer Foundation		CA098543 CA114004	93.395 93.395		149,802.06 220,484.49	149,802.06 220,484.49
		Promoting Treatment Adherence in Adolescent Leukem			CA114004 CA119162	93.395	53,078.18	220,484.49 164,362.33	220,484.49 672,180.75
		Fromoung Freatherit Adherence in Addrescent Leaketti		Children's Hospital Los Angele: Children's Hospital of Philadelphia	OA118102	e3.393	125.372.00	104,302.33	072,100.75
				Dana Farber Cancer Institute			60,795.93		
				University of Pittsburgh			73,386.60		
				University of Texas Medical Branch			195,185.71		

	T	ı	1		1			1	
					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
		HSCT-CHESS to Enhance Hematopoietic Transplant Recover Adult Neurobehavioral Late Effects of Pediatric Low Gra	New England Medical Center Hospita Baylor College of Medicine		CA119196 CA132899	93.395 93.395		16,639.19 22,223.86	16,639.19 22,223.86
		Virotherapy for Neuroblastoma Stem Cell	Baylor College of Medicine		CA132699 CA133663	93.395		35,173.25	35,173.25
		SapC-DOPS Nanovesicles for Treating Glioblastoma Multif	Bexion Pharmaceuticals		CA136017	93.395		91,601.28	91,601.28
		Targeted Improvement in Stem Cell Therapy for Leukemia			CA157537	93.395		137,109.65	137,109.65
				Cancer Treatment Research Total			507,818.42	987,662.49	1,495,480.91
	Cardiovascular Diseases Research	Training in Cardiovascular Biology	University of Cincinnat		HL007382	93.837		53,504.78	53,504.78
	Outdovaboular Discussion Noscardi	Pediatric Cardiomyopathy Registr	University of Miam		HL053392	93.837		37,296.00	37,296.00
		Cardiac Myosin Binding Protein-C: Structure, Function.	University of Vermont		HL059408	93.837		734,334.76	734,334.76
		Molecular pathways controling cardiac gene expressic			HL060562	93.837		413,828.01	413,828.01
		Cardiac hypertrophic intracellular signaling pathway			HL062927	93.837 93.837		519,047.21	519,047.21
		Genetic Mechanisms of Cardiac Disease in the Youn Signaling processes underlying cardiovascular functio		University of Cincinnat	HL069712 HL069779	93.837	129,946.36	183,687.70 1,752,969.92	183,687.70 1,882,916.28
		Molecular Mechanisms of Valve Development and Diseas		Oniversity of Ciricinnat	HL074728	93.837	129,940.30	(730.88)	(730.88)
		CV Disease in Adolescents with Type 2 Diabete			HL076269	93.837		(33,807.00)	(33,807.00)
		Genetic and Molecular Signaling in Heart Failur	University of Cincinnat		HL077101	93.837		112,099.02	112,099.02
		Calpain and Calpastatin Regulation of Reperfusion Injur		Phoenix Children's Hospita	HL077653	93.837	7,152.02	7,192.41	14,344.43
		Mech of Vascular Dysfunction in Obesity & the Metaboli Mitochondrial Regulated Cardiac Myocyte Deat			HL080447 HL081104	93.837 93.837		106,340.44 (15,401.01)	106,340.44 (15,401.01)
		Tbx20 Regulation of Heart Valve Developmer			HL082716	93.837		5,021.76	5,021.76
		Twist 1 regulation of valve progenitor			HL082716	93.837		411,027.30	411,027.30
		Preoperative Therapy for Prevention of Postoperative Lo			HL085057	93.837		316,950.12	316,950.12
		Genetic & Developmental Basis of Pediatric Aortic Valv			HL085122	93.837		180,850.23	180,850.23
		Pediatric Cardiomyopathy Specimen Repositor		New England Research Institutes Inc	HL087000	93.837	3,192.52	888,616.86	942,082.83
				University of Miam	111 007000	93.837	50,273.45	(4.404.07)	44.404.070
		Cardiomyocyte Toxicity and Heart Failure in Desmin Rel: Calcium as a Molecular Signal in the Hear	Temple University		HL087862 HL089312	93.837		(1,184.87) 372,745.71	(1,184.87) 372,745,71
		Defining the Role of Necrotic Cell Death in the Prog.	Temple University		HL092737	93.837		2.746.78	2.746.78
		The Influence of Child Care Center Envir on Physical Ac			HL088053	93.837		114,854.11	114,854.11
		Modifying Dietary Behavior in Adolescents with Elevate	University of Cincinnat		HL088567	93.837		54,760.30	54,760.30
		Role of the embryonic node for cardiac development and			HL088639	93.837		261,636.82	261,636.82
		Developing an In Vivo Adherence Interventio		Rand Corporatior Texas A&M Research Foundatior	HL089524	93.837	7,635.82 5,589.37	63,981.79	77,206.98
		Elucidation of molecular networks required to limit ca		rexas A&W Research Foundation	HL091126	93.837	5,589.37	231,815.49	231.815.49
		Effects_Dietary Fat on Post-Prandial Vascular Function			HL091174	93.837		160,231.47	160,231.47
		Mechanisms of Vasopressin-Mediated PVR after Fetal Bypa			HL093683	93.837		137,830.97	137,830.97
		Novel Model of Adult Epithelial Stem Cell Expansio			HL093706	93.837		193,175.30	193,175.30
		Therapeutic Hypothermia after Pediatric Cardiac Arre:	University of Michigan		HL094345	93.837		27,778.47	27,778.47
		The non-hypertrophic role of calcineurin in regulating Role of IP-3 Mediated Calcium Release in Cardiac Hyper			HL095353 HL097186	93.837 93.837		66,406.43 215,317.98	66,406.43 215,317.98
		Regulation of Cardiac Gene Expression by the L-type Ca			HL097551	93.837		65,051.03	65,051.03
		Role of Rb/p16 Pathway in Pulmonary Progenitor Cell Reg		University of Cincinnat	HL097609	93.837	26.378.00	4.196.70	30.574.70
		Role of TAK1 Signaling Network in Cardiac Hypertroph			HL098076	93.837	,	86,787.77	86,787.77
		Understanding Mechanisms of Fontan Failure and Key Prec	Georgia Tech		HL098252	93.837		15,105.12	15,105.12
		Hypoplastic Left Heart Syndrome: Rheumatic Heart Diseas		University of Oklahoma	HL098634	93.837	59,305.04	207,447.72	266,752.76
		Cincinnati Cell Characterization Core Cardiac Structure and Function in Early Familial Cardior	University of Maryland	University of Cincinnat	HL099997 HL102244	93.837 93.837	12,546.91	180,149.64 158.558.74	192,696.55 158.558.74
		Myocardial Protection during Fetal Bypass: Role of Cali			HL102244 HL103054	93.837		4,225.20	4,225.20
		Regulation of Foxp3 Expression by DNA Methylation in Mo			HL103087	93.837		27,404.58	27,404.58
		Admixture Mapping in African Amerian Asthmatic Childre			HL103165	93.837		50,813.94	50,813.94
		The Molecular Basis for High Density Lipoprotein Hetero	University of Cincinnat		HL104136	93.837		55,910.55	55,910.55
		Regulation of Hematopoietic Stem Cell Self Renew			HL104458	93.837		145,667.22	145,667.22
		miR-21 in the Pathogenesis of Asthma Accelerated CV Aging in Youth Related to CV Risk Facto			HL104892 HL105591	93.837 93.837		27,490.92 122,402.90	27,490.92 122,402.90
		Thrombospondin 4 regulates adaptive ER stress respons			HL105924	93.837		318,378.72	318,378.72
		Macrophage-based Human Gene Therapy for Hereditary PA			HL106134	93.837		86.596.83	86.596.83
		Molecular Mechanisms of Arterial-Venous Differentiatio			HL107369	93.837		36,502.32	36,502.32
				Cardiovascular Diseases Research Total			302,019.49	9,167,614.28	9,469,633.77
	Centers for Disease Control & Prevention Investigations & Tech. Ass	The Effect of Improved Hosp Reimbursment for Rt-PA in OI	University of Cincinnat		CCU319276	93,283		9.886.13	9.886.13
	Centers for Disease Control & Flevention Investigations & Fech. Ass	Hemophilia Prevention Networl	Hemophilia Foundation of Michigai		DD000203	93.283		20.522.84	20.522.84
		SEARCH for Diabetes in Youth2: Ohio Site		University of Colorado	DP000248	93.283	1,259.19	184,026.19	185,285.38
		Myositis Registry	The Myositis Association		DP001743	93.283		70,541.32	70,541.32
				Centers for Disease Control & Prevention Inv Tech. Asst. Total	estigations &		1,259.19	284,976.48	286,235.67
	Child Abuse and Neglect State Grants	ODJFS "Beyond the Silence" "PSANE" training and Tech Su			G-1011-06-0589	93.669		85,000.39	85,000.39
				Child Abuse and Neglect State Grants Total		-	-	85,000.39	85,000.39
	Child Health and Human Development Extramural Researc	Characterization of Rac Proteins in Myeloid Leukemogene	Yale University		HD000850	93.865		17,135.71	17,135.71
		Pediatric Physician Scientist Program Awar	,	Children's Hospital Bostor	HD000850	93.865	93,837.55	422,147.05	1,264,886.20
				Duke University			8,921.24		
				University of CA, San Diegc University of CA, San Francisco			50,255.18 174,087.78		
				University of CA, San Francisco			174,087.78		

					Federal Grant		1	1	
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
Gov Agency	GOV Branch	Award Title	Pass-Inrough Grantor	University of Colorado	Number	CFDA	62,641.18	rea Exp	iotai Exp
				University of Colorado University of Michigan			71.890.71		
				University of Pittsburgh			56,459.59		
				University of Texas Southwesterr			74.090.40		
				University of Washington			30,394.28		
				Washington University			130,313.94		
				Yale University			89,847.30		
		Genetic Influence on Cognitive and Behavioral Recovery			HD001097	93.865	,	101,582.25	101,582.25
		The Physiology of Placental Lactogen Bridg			HD007447	93.865		30,137.20	30,137.20
		Training In Developmental And Perinatal Endocrinolog			HD007463	93.865		133,641,24	133,641.24
		Aspects of Blastocyst Implantation			HD012304	93.865		232,474,45	232,474,45
		Neonatal Resuscitation and Preterm Lung Injur		University of Western Australia	HD012714	93.865	80,228.44	140,964.56	221,193.00
		The Role of Human Milk in Infant Nutrition and Healt		Boston College	HD013021	93.865	396,434.30	704,257.04	1,465,643.64
				Inst Nac Ciencias Med Y Nutricior			355,207.16		
				University of Cincinnat			9,745.14		
		Eunice Kennedy Schriver NICHD cooperative Multicenter N		•	HD027853	93.865		197,524.34	197,524.34
		Pediatric Center for Gene Expression and Developmer			HD028827	93.865		499,883.57	499,883.57
		CHMC Clinical Pharmacology Research Uni			HD037249	93.865		5,214.91	5,214.91
		fMRI of Normal Language Development in Childre			HD038578	93.865		210,652.09	210,652.09
		Understanding Social Status Impact on Adolescent Healt	Massachusetts General Hospita		HD041527	93.865		252,763.13	252,763.13
		Long Term Functional Outcomes Following Early Childhoo		Case Western Reserve University	HD042729	93.865	7,265.44	385,277.31	478,519.01
				Nationwide Childrens Hospita			85,976.26		
		Cadherin-based Actin Assembly in the Xenopus Embry			HD044764	93.865		326,721.00	326,721.00
		Ectoderm Formation in the Early Xenopus Embry			HD045737	93.865		298,415.79	298,415.79
		Childhood Residential Injury and Caregiver Supervisio			HD045770	93.865		(7,060.51)	(7,060.51)
		Training Program in Organogenesi:			HD046387	93.865		190,376.02	190,376.02
		Towards Improved Clinical Trials in Cerebral Pals			HD049552	93.865		154,342.52	154,342.52
		ATN Coordinating Center	University of Alabama-Birminghan		HD040533	93.865		55,855.33	55,855.33
		Optimizing MNF Therapy in Pediatric Transplants Patient			HD050387	93.865		111,936.00	111,936.00
		BIRCWH Fellowship	University of Cincinnat		HD051953	93.865		134,409.52	134,409.52
		Preventing Teen Pregnancy			HD052533	93.865		466,239.27	466,239.27
		Social Competence With Peers Following Early Childhood			HD055218	93.865		51,336.60	51,336.60
		Novel Adherence Measurement and Intervention in Childre			HD057333	93.865		147,396.92	147,396.92
		Mechanisms of Fetal Inflammatory Response Syndrome Indu		University of Western Australia	HD057869	93.865	141,038.96	214,478.40	355,517.36
		The Host Reponse to Calfactant for Direct Acute Lung Ir			HD058246	93.865		13,958.52	13,958.52
		Genome Wide Association Study of Bone Mineral Accretio	Children's Hospital of Philadelphia		HD058886	93.865		210,452.30	210,452.30
		Novel genetic and salivary glycan biomarkers for risk (Boston College	HD059140	93.865	224,615.30	424,538.99	706,477.53
				University of Alabama-Birminghan			57,323.24		
		Therapy of Neuronopathic Gaucher Disease			HD059823	93.865		150,288.41	150,288.41
		Aging in Adults With Down Syndrom€		University of Wisconsin	HD059848	93.865	54,818.80	28,448.62	83,267.42
		20-year intergenerational longitudinal followup of fem			HD060604	93.865		69,749.44	69,749.44
		Reading ICARD: Interventions for Children with Attentio	University of Texas -Houstor		HD060617	93.865		348,647.35	348,647.35
		Hyaluronan Regulation of Microbial Host Defense.	Cleveland Clinic		HD061918	93.865		47,539.58	47,539.58
		Sterol and Isoprenoid Diseases Rare Diseases Consortiui	Oregon Health Sciences University		HD061939	93.865		89,079.72	89,079.72
		RNA Biosignatures in the Emergency Evaluation of Febril	Wayne State University		HD062477	93.865		18,193.28	18,193.28
		Parental Adherence to CF Homecare: Research Chaplaincy			HD062642	93.865		96,495.65	96,495.65
		Xenbase: a Xenopus Model Organism Databas		University of Calgary	HD064556	93.865	433,260.17	277,838.05	711,098.22
		Injury Prevention in a Home Visitation Populatio		Child Health and Human Development Extramu	HD066115	93.865	2,688,652.36	337,442.70 7,590,774.32	337,442.70 10,279,426.68
				Child Health and Human Development Extramu	rai Research Total		2,088,032.30	7,590,774.32	10,279,426.66
	Developmental Disabilities Basic Support and Advocacy Gran	Project SEARCH			06-3/10	93,630		122.088.12	122.088.12
	Developmental Disabilities Basic Support and Advocacy Gran	Ohio Disability Impact Study			OSU 60026471	93.630		17.957.75	17,957.75
		Onio disability impact study		Developmental Disabilities Basic Support and		93.030		17,937.73	17,937.73
				Grants Total	navoua,			140,045.87	140,045.87
								,	,
	Diabetes, Digestive, and Kidney Diseases Extramural Researc	Research Training in Pediatric Nephrolog			DK007695	93.847		137,591.68	137,591.68
		Pediatric Gastroenterology and Nutrition Training Gran			DK007727	93.847		361,627,58	361,627,58
		Studies of Gaucher Disease: A Prototype Lipidosi			DK036729	93.847		570,690.14	570,690.14
		Expression and Function of the Guanylin Ligand Famil			DK047318	93.847		6.059.08	6.059.08
		Behavioral & Nutrition TX to Help CF Preschoolers Grov		Nationwide Childrens Hospita	DK054915	93.847	5,234.19	309,898.45	327,584.39
				University of Michigan			12.451.75	,	,,,,
		The Plasminogen System and Liver Repa			DK055710	93.847		95,337.50	95,337.50
		Behavioral Rx & Nutrition in Pediatric Chronic Diseas			DK059492	93.847		183,001.53	183,001.53
		Behavioral Treatment for Dietary Adherence in Childre			DK059973	93.847		232,374.74	232,374.74
		CRN in Non-Alcoholic Steatohepatitis (NASH CRN	Case Western University		DK061732	93.847		100,305.96	100,305.96
		Development of the Metanephric Mesenchym			DK061916	93.847		44,861.91	44,861.91
		Clinical Center for Cholestatic Liver Disease i		The Hospital for Sick Childrer	DK062497	93.847	181,769.05	432,493.13	614,262.18
		Research Training in Child Behavior and Nutritio			DK063929	93.847		218,427.48	218,427.48
		Immunologic Dystunction in Biliary Artresi:			DK064008	93.847		341,987.01	341,987.01
		Chronic Kidney Disease in Childrer	Children's Mercy Hospita		DK066143	93.847		84,655.78	84,655.78
		Mechanistic Analysis of Eosinophilic Esophagiti:			DK067255	93.847		2,149.89	2,149.89
		Cytokine Regulation of Growth Hormone Signalin			DK068164	93.847		119,407.08	119,407.08
		Bacterial Survival in the Mammalian Urotheliur			DK068359	93.847		99,026.00	99,026.00
		Intralumental Effect on Cholesterol Absorption/ Synthe:		University of Cincinnat	DK068463	93.847	164,046.38	118,705.84	282,752.22
		Self-Management of Type 1 Diabetes During Adolescenc		Nemours Children's Clinic	DK069486	93.847	14,724.00	330,768.26	478,253.12

			1	_	Federal Grant	1 1		1	
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
GOV Agency	GOV Branch	Award Title	Pass-Inrough Grantor		Number	CFDA		rea Exp	i otai Exp
		Molecular Basis of Bladder Organogenesi		University of Miam	DK069608	93.847	132,760.86	28,588.71	28,588.71
		Implications of the Ask1/Jnk Pathway in Ar			DK069749	93.847		61,240.36	61,240.36
		Murine Atlas of Genitourinary Smooth Muscle Developmer		Columbia University	DK070219	93.847	128,652.56	(17,102.76)	472,426.67
				Duke University			131,883.25	(,)	,
				University of Wisconsin			154,334.83		
				Vanderbilt University			74,658.79		
		Global Gene Expression Atlas of the Developing Kidne		•	DK070251	93.847		9,068.03	9,068.03
		Beta Cell Function in Adolescents with Type II Diabete			DK070775	93.847		31,808.97	31,808.97
		Molecular Basis of Liver Developmen			DK070858	93.847		278,347.57	278,347.57
		Endothelial Progenitor Cell Recruitment In Diabetic Mic			DK072446	93.847		(22,423.90)	(22,423.90)
		Adolescent Bariatrics: Assessing Health Benefits & Risk		Baylor College	DK072493	93.847	155,374.38	946,481.58	1,436,633.83
				Nationwide Childrens Hospita			58,292.06		
				University of Alabama-Birminghan			15,801.11		
				University of Cincinnat			103,814.05		
				University of Pittsburgh			58,385.75 98.484.90		
		Dethanaia Manhariana of Mara Indiana d Diliana Assari		University of Washington	DK072858	93.847	98,484.90	7.331.26	7 004 00
		Pathogenic Mechanisms of Virus Induced Biliary Atresi Depression in Children and Adolescents with Type 1 Diab			DK072858 DK073340	93.847		7,331.26 35.347.25	7,331.26 35.347.25
		Bone Health in Pediatric Crohn Disease: A Low Magnitud	Children's Hospital of Philadelphia		DK073340 DK073946	93.847		12.248.19	12.248.19
		Endothelial Progenitor Cell Biology in Type I Diabete	Criticien's Hospital of Frilladelphik		DK074055	93.847		2,281.20	2,281.20
		Randomized Intervention for Children with Vesico Ureter	University of Buffalc		DK074063	93.847		28,951.39	28,951.39
		IL-13 and Eosinophilic Esophagitis	Offiversity of Bullaic		DK076893	93.847		282,211.70	282,211.70
		Adioponectin and Cardiovascular Disease in the CKiD Ch		Children's Mercy Hospita	DK076957	93.847	11.125.66	153,507.05	225,573.18
		Adoportodin and Gardovassada Bissado in the OND On		University of Texas Southwesterr	Bitorosor	00.011	60.940.47	100,007.00	220,070.10
		Young Stem Cell Potential in Aged Mic			DK077762	93.847	,-	87.350.94	87.350.94
		SEARCH Nutrition Ancillary Study (SNAS), Ohio Subcontrac	University of North Carolina		DK077949	93.847		38,249.78	38,249.78
		Dissecting Dendritic Cell Function in Autoimmune Diabet			DK078179	93.847		354,669.21	354,669.21
		Digestive Health Center, Bench to Beside Research in Pe		University of Cincinnat	DK078392	93.847	85,508.04	1,035,327.41	1,120,835.45
		Biomarkers for Inflammatory Bowel Disease Behavior and		Emory University	DK078683	93.847	35,480.37	483,181.08	650,805.28
				Univ of North Carolina at Chapel Hi			132,143.83		
		Angiogenic peptide scaffolds to enhance diabetic wound	University of Cincinnat		DK078814	93.847		(16,379.18)	(16,379.18)
		Behavioral Treatment of Nonadherence in Pediatric Inflai			DK079037	93.847		129,051.94	129,051.94
		Altered gene expression using microarray in focal segme			DK079545	93.847		10,277.12	10,277.12
		Adolescent Bariatrics: Controlled Longitudinal Study of		Baylor College	DK080020	93.847	46,296.28	415,964.71	490,479.33
				Nationwide Childrens Hospita			11,771.91		
				University of Pittsburgh			16,446.43		
		Parenting & Control Among Young Children with T1 Diabet			DK080102	93.847		29,814.34	29,814.34
		Dietary Intake & Beh in Adol Bariatric Surg Pt	University of Pennsylvania		DK080738	93.847		100,936.72	100,936.72
		Medication Adherence in Children Who Had Liver Transpla Mammalian Foregut and Liver Developmer	Mount Sinai Medical Center		DK080740 DK080823	93.847 93.847		85,326.71 337.517.09	85,326.71 337.517.09
		Bio Determinants of Steatohepatitis after Adol Baria Si			DK080823 DK080888	93.847		175,976.06	175.976.06
		Family based, psychosocial intervention for depressed y			DK080666 DK081711	93.847		65.571.70	65.571.70
		CDC42GAP in Insulin Signaling in Hepatocytes			DK082108	93.847		52,175.61	52,175.61
		Mast Cell-Mediated Intestinal Permeabilit			DK082113	93.847		1,141.78	1,141.78
		Progression of Acute Kidney Injury to Chronic Kidney Di	Yale University		DK082185	93.847		67.171.02	67.171.02
		Developmental Paradigms to Direct Human Endoderi	,		DK083202	93.847		48,509.43	48,509.43
		Mechanisms of Intestinal Stem Cell Expansion Following		University of Michigan	DK083325	93.847	1,005.27	456,663.42	457,668.69
		Defining Preadipocyte Signature Gene	University of Toledc	y <u>y</u>	DK083643	93.847	,	13,831.58	13,831.58
		Biological Basis of Phenotypes & Clinical Outcomes in E	*		DK083781	93.847		332,279.37	332,279.37
		Primary biliary cirrhosis: Molecular genetics and micro		University of Cincinnat	DK084054	93.847	6,173.62	473,204.08	479,377.70
		SPDEF in Intestinal Differentiation			DK084167	93.847		67,134.19	67,134.19
		Role of Ileum in Reducing Obesity Related Comorbiditie			DK084310	93.847		153,470.89	153,470.89
		Cell Phone Adherence Trial for Underserved T1DM Yout	Univ of North Carolina at Chapel Hi		DK085483	93.847		30,742.59	30,742.59
		Forecasters of future and progressive chronic kidne	Ohio State University		DK085673	93.847		18,406.56	18,406.56
		Promoting Treatment Adherence in Pediatric Inflammato			DK087822	93.847		68,237.52	68,237.52
		Intracellular Signaling Pathways and Virus Induced Bili			DK087974	93.847		72,878.87	72,878.87
		Cincinnati Center for Excellence in Molecular Hematolog			DK090971	93.847		507,193.67	507,193.67
		Dendritic Cells in the Breaking of Peripheral Toleranc			DK090978	93.847		224,727.62	224,727.62
		The Molecular Determinants of Virus Induced Biliary Atr		Diabetes, Digestive, and Kidney Diseases	DK091566	93.847		7,869.99	7,869.99
				Research Total	Extramurar		1,897,559.79	11,555,729.46	13,453,289.25
	Disabilities Preventior	Spina Bifida Registry Demo Projec			DD000387	93.184		50,955.37	50,955.37
				Disabilities Prevention Total		•	-	50,955.37	50,955.37
	Discovery and Applied Res. for Technological Innovations	Center for point-of-care technologies research for STD	The Johns Hopkins University		EB007958	93.286		50,326.63	50,326.63
	Improve Human Health	POC-CENT	University of Cincinnat	Discourse and Applied Basses 1.7 T.	EB007954	93.286		19,997.31	19,997.31
				Discovery and Applied Research for Tech Innovations to Improve Human Health Tot	noiogicai al		-	70,323.94	70,323.94

	T.				•				
					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Drug Abuse and Addiction Research Program	Effects of Neonatal MDMA on Brain and Behavio			DA021394	93.279		142,988.54	142,988.54
		Endocannabinoid Signaling During Early Pregnanc			DA006668	93.279		390,959.10	390,959.10
		Innovative Modeling of Puberty and Substance Use Ris		Pennsylvania State University	DA019965	93.279	1,690.62	18,004.60	19,695.22
		Clinical Trials Network, Ohio Valley Nod	University of Cincinnat		DA013732	93.279		25,525.99	25,525.99
				Drug Abuse and Addiction Research Programs	s Total		1,690.62	577,478.23	579,168.85
	Drug-Free Communities Support Program Grant	DFC Support Program - POCWA			SP014669	93.276		128,986.55 128,986.55	128,986.55 128,986.55
				Drug-Free Communities Support Program Gra	nts I otal		•	128,986.55	128,986.55
	Emergency Medical Services for Children	EMSC Network Development Demonstration Projec	University of California-Davis		MC00001	93.127		97.334.52	97.334.52
	Emergency Medical Services for Children	Defining Quality Performance Measures for Pediatric Car	Offiversity of California-Davis	Children's Hospital of Philadelphia	MC16597	93.127	6.386.92	59.803.67	78.475.45
		Delining Quality i enormance weasures for i ediatric car		Medical College of Wisconsir	WIC 10337	33.127	3,979.86	33,003.07	10,413.43
				University of Utah			8.305.00		
		Chesapeake Applied Research Network for EMS(Children's National Medical Cente	Chiroloxy of Clair	MC00006	93.127	0,000.00	25.181.00	25.181.00
				Emergency Medical Services for Children Tota			18,671,78	182,319.19	200,990,97
									,
	Environmental Health	Center for Environmental Genetic:	University of Cincinnat		ES006096	93.113		20,904.51	20,904.51
		Training Grant in Teratology			ES007051	93.113		276,182.17	276,182.17
		Environmental Carcinogenesis and Mutagenesi	University of Cincinnat		ES007250	93.113		102,812.07	102,812.07
		Environmental Toxins and Uterine Gene Expressio			ES007814	93.113		281,402.00	281,402.00
		Pooled Analysis of (OP) Metabolites & DDe & Birt	University of California-Berkeley		ES009605	93.113		5,281.15	5,281.15
		Moleculary Epidemiology in Children's Environmental He	University of Cincinnat		ES010957	93.113		88,822.75	88,822.75
		Pathways to Mutagenesis in Vivo and in Stem Cell	University of Cincinnat		ES012695	93.113		(177.15)	(177.15)
		BCERC Data Management Supplemen	University of Cincinnat		ES012770	93.113		(50,008.54)	(50,008.54)
		A CommBased Trial to Prevent Lead Poisoning & Injurie		University of Cincinnat	ES014575	93.113	8,899.96	429,955.31	438,855.27
		Role of Environmental Chemicals on Lactation Outcome			ES014691 ES015559	93.113 93.113		152,892.89	152,892.89
		Early Lead Exposure, ADHD and Persistent Criminality: R Functional Genomics of Chemical Induced Acute Lung Inju	University of Cincinnat University of Pittsburgh		ES015559 ES015675	93.113		154,639.45 29.766.14	154,639.45 29.766.14
		Effects of Lead, Manganese and Stress During Developmer	Oniversity of Fittsburgh		ES015689	93.113		312.895.46	312.895.46
		Mechanism of PM Induced Dendritic Cell Activation	The Johns Hopkins University		ES015903	93.113		382,158,62	382,158,62
		Mechanisms of Pesticide-Induced Neurobehavioral Deficit	University of Medicine & Dentistry of N.		ES015991	93.113		31.892.57	31.892.57
		Genomic and proteomic biomarkers of biologic responses	University of Alabama-Birminghan	University of Cincinnat	ES016003	93.113	2,719.63	53.548.41	56.268.04
		Prenatal Low Level Tobacco Exposur	Pennsylvania State University	Chiroloxy of Chichina	ES016304	93.113	2,7 10.00	20,705.07	20,705.07
		Environmental Exposure: Susceptibility Alleles in a DN	University of Cincinnat		ES016625	93.113		3,542.00	3,542.00
		Exposure assessment of biomarkers of polyfluoroalkyl co	University of Cincinnat		ES017176	93.113		397.12	397.12
		Impact of peripubertal exposure to xenohormones on fat		University of Cincinnat	ES017315	93.113	7,346.42	123,821.29	131,167.71
		Intervention to Reduce Body Burden of PCBs in Resident	University of Cincinnat		ES019206	93.113		64,099.67	64,099.67
		Continued studies of environmntl impact on puberty:GUF		University of Cincinnat	ES019453	93.113	136,543.83	405,745.27	542,289.10
				Environmental Health Total			155,509.84	2,891,278.23	3,046,788.07
	Enterprise December December in the Newsonian	Missauria Antidia la Navadibarrata			NOODOOAO	93.853		047.007.57	047 007 57
	Extramural Research Programs in the Neurosciences an	Mitogenic Activities in Neurofibromatosi			NS028840	93.853		217,637.57	217,637.57
	Neurological Disorders	Hemorragic & Ischemic Stroke among blacks and white Genetic and Environmental Risk Factos for Hemrrhagi	University of Cincinnat		NS030678 NS036695	93.853		77,723.50 71.885.93	77,723.50 71.885.93
		Parkinson Disease Collaborative Study of Genetic Linkag	University of Cincinnat Indiana University		NS036695 NS037167	93.853		71,885.93 35.112.46	71,885.93 35.112.46
		Apoptosis and Renewal of Neural Progenitor Cell	Yale University		NS037167 NS038296	93.853		41.034.47	41.034.47
		Familial Intracranial Aneurysm Study	University of Cincinnat		NS039512	93.853		29.530.00	29.530.00
		Silent Cerebral Infarct Multi-Center Clinical Tria	Washington University		NS042804	93.853		5,916.95	5.916.95
		Roles of Gsh1 & Gsh2 in Telencephalic Neurogenesi			NS044080	93.853		315.988.61	315.988.61
		Recanalization Therapies and markers of Outcomes in Acı	University of Cincinnat		NS044283	93.853		168,685.69	168,685.69
		fMRI of Language Recovery Following Stroke in Adult	University of Cincinnat		NS048281	93.853		42,450.84	42,450.84
		· · · · · · · · · · · · · · · · · · ·	•						

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
y		Impact of Initial Therapy and Response on Long Term Ou		Arkansas Children's Hospita	NS045911	93.853	22,656.79	1,269,342.19	1,959,995.06
				Baylor College of Medicine			9,998.89		
				Case Western Reserve University			7,053.54		
				Children's Healthcare of Atlanta			7,779.36		
				Childrens Hospital of Philadelphia			38,297.75		
				Children's Hospital of Philadelphia			12,779.10		
				Children's Hospital of Pittsburgh			14,178.35		
				Children's Memorial Hospita Children's National Medical Cente			664.79 110.514.68		
				Children's National Medical Cente Children's Research Institute			110,514.68 82.970.14		
				Cook Children's Health Care System			13.692.00		
				Eastern Virginia Medical Schoo			8.274.11		
				Medical College of Wisconsir			5,916.72		
				Miami Children's Hospital Research Ins			22,469,90		
				Montefiore Medical Cente			128.046.00		
				Nationwide Childrens Hospita			29,007.53		
				Nemours Children's Clinic			23,526.52		
				Oregon Health & Science University.			6,820.83		
				Seattle Children's Hospita			9,350.61		
				St Joseph's Hospital & Medical Cente			19,972.00		
				The Children's Hospital Association			17,644.00		
				The Women&Childrens Hosp. of Buffalc			3,906.84		
				University of Alabama-Birminghan			3,973.81		
				University of California			39,123.13 5.017.42		
				University of Pittsburgh University of Tennessee			1,470.00		
				University of I terinessee University of Utah			1,470.00		
				Washington University			18.096.00		
				Wayne State University			5,826.22		
				Yale University			7.345.71		
		Genetic Mechanisms of Acute Necrotizing Encephalopath			NS050331	93.853	, , ,	1,609.97	1,609.97
		Spinal Abnormalities in Neurofibromatosis Type	University of Utah		NS050509	93.853		58,383.36	58,383.36
		Drug & Non-Drug Treatment of Pediatric Chronic Headach			NS050536	93.853		301,082.57	301,082.57
		Regulation and mechanisms of synatic vesicle exocytos			NS054750	93.853		243,477.75	243,477.75
		The Role of SLITRK1 in Tourette and Related Disorder	Yale University		NS056276	93.853		36,265.05	36,265.05
		Rac GTPases in the Mammalian Brain Developmer			NS056435	93.853		320,658.69	320,658.69
		Cincinnati Center for Neurofibromatosis Researc		University of Cincinnat	NS057531	93.853	206,260.73	947,992.49	1,451,798.28
		000 T # F. IF & W. II & W. II		University of Minnesota	110000001	00.050	297,545.06	10 100 07	40 400 07
		CD 8 T cell mediated disruption of blood brain tight ju	University of Cincinnat		NS060881	93.853 93.853		18,460.67 43.569.30	18,460.67 43.569.30
		Identification of Drug Targets for NF ⁻ Sodium Channel Gene Variation in the Treatment of Epile	Dartmouth		NS060940 NS062756	93.853		43,569.30 310,460.36	43,569.30 310,460.36
		Contributions of Aberrant Granule Cells Integration to			NS062806	93.853		319,967.30	319,967.30
		Genetic Therapy for CNS Manifestations in MPS I via BBB			NS064330	93.853		316,662,77	316,662,77
		Selective disruption of hippocampal dentate granule or			NS065020	93.853		227.896.73	227.896.73
		Regulation of Sensory-Motor Connectivity by Semaphorir			NS065048	93.853		327,637,73	327,637,73
		LDN: Epidemiology and Natural History of Wolman and Chr	University of Minnesota		NS065768	93.853		97,275.06	97,275.06
		Endogenous CNTF Receptors and Adult, In Vivo Neurogene	University of Cincinnat		NS066051	93.853		17,370.72	17,370.72
		Pilot Trial of Bumetanide for Neonatal Seizure	Children's Hospital Bostor		NS066929	93.853		5,872.04	5,872.04
		Longitudinal DTI study in Children Treated for Congenit		Washington Univ. of St. Louis	NS066932	93.853	69,849.12	222,264.19	292,113.31
		Molecular control of neurogenesis in the adu			NS069893	93.853		416,174.56	416,174.56
		Motor cortex dysfunction in migraini			NS072817	93.853		101,122.48	101,122.48
				Extramural Research Programs in the Neuros	ciences and		4 00 4 00 = -		= 0=0 010
				Neurological Disorders Total			1,264,307.78	6,609,512.00	7,873,819.78

	1			1					
					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
	Food and Drug Administration Research	Triptorelin for Ovary Protection in Childhood Lupu		ACM Clinical Trials	FD002369	93.103	2.592.70	60.947.32	99.535.23
	Food and Drug Administration Research	Imptoreill for Ovary Protection in Childhood Eupu		Children's Hospital Los Angele:	FD002309	93.103	15.316.80	00,947.32	99,535.23
				Fundação Faculdade De Medicina			20.678.41		
		Phase 3 Trial of Coenzyme Q10 in Mitochondrial Disease	University of Florida		FD003032	93.103		79,703.00	79,703.00
		Phase III Trial of Sirolimus in Lymphangioleiomylmatos	University of Cincinnat		FD003362	93.103		104,052.85	104,052.85
		IL-1 Trap for Treatment of Familial Mediterranean Feve			FD003435	93.103		76,574.60	76,574.60
		Phase II Study of Rapamycin for Complicated Vascular An Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumo			FD003712 FD003717	93.103 93.103		276,904.62 140.707.90	276,904.62 140,707.90
		Fliase I Study of HSV 17 to III Fediatile Notificing Solid Tullik		Food and Drug Administration_Research Total	FD003/1/	93.103	38.587.91	738.890.29	777,478.20
							,	,	,
	Health Care and Other Facilitie:	HRSA Equipment			HF19356	93.887		494,999.92	494,999.92
				Health Care and Other Facilities Total				494,999.92	494,999.92
	Haalib Oarras Oarrab with Darras	AADODO Dissessioner Frank Deservative Constitution	The Univ of Texas - San Antonic		AI070412091	00.000		49.098.74	49.098.74
	Health Careers Opportunity Progran	AADCRC Discretionary Funds Proposal: The Genetic/Genomi	The Univ of Texas - San Antonic	Health Careers Opportunity Program Total	AI070412091	93.822		49,098.74	49,098.74
				ricular duració apportantly r rogram rotal				40,000.14	40,000.14
	Human Genome Research	Computational Tools for Bayesian Mixture Modeling of Fu	University of Cincinnat		HG003749	93.172		(861.28)	(861.28)
				Human Genome Research Total		_		(861.28)	(861.28)
	International Research and Research Training	Facesty California de des	Manufacture Italian in the Committee	Christian Medical Center	T14/007000	00.000	2 200 40	21.591.08	04.054.50
	International Research and Research Training	Fogarty-Schlaudecke	Vanderbilt University	International Research and Research Training	TW007988	93.989	3,060.48 3,060.48	21,591.08 21.591.08	24,651.56 24,651.56
				international research and research framing	otai		3,000.40	21,331.00	24,031.30
	Lung Diseases Research	Pulmonary and Cardiovascular Development Training Grai			HL007752	93.838		212,897.99	212,897.99
		Role of Surfactant Protein-C and innate Lung Defense			HL050046	93.838		354,764.35	354,764.35
		Structure/ Function Analyses of SP-B in Transgenic Mice			HL056285	93.838		470,065.48	470,065.48
		Asthma Positional Candidate Genes in Mice and Human			HL067736	93.838		143,751.64	143,751.64
		Genetic Analysis of Hyperoxia Induced Acute lung Injur			HL075562	93.838		406,254.24	406,254.24
		Role of Cockroach Proteases in Airway Inflammatio			HL075568	93.838		(1,234.40)	(1,234.40)
		Interleukin-13 in Experimental Asthm:			HL076383	93.838		(6,061.29)	(6,061.29)
		Role of Rb Family in Lung Epithelial Response to Injur			HL079193	93.838		330,774.10	330,774.10
		Lipid Mediators and Dysregulated Inflammation in C Alveolar Cell Dysfunction and Pulmonary Fibrosi			HL079312 HL082757	93.838 93.838		89,955.15 106,317.07	89,955.15 106,317.07
		WEB-based Respiratory Education about Tobacco or Healt	InterVision		HL083540	93.838		(2.61)	(2.61)
		Fox Transcription Factors in Development of Pulmonary C	IIItel VISIOII		HL084151	93.838		520,476.51	520,476.51
		Role of HIF-1alpha in Fetal Lung Epithelial Differentia			HL084376	93.838		517.004.08	517.004.08
		Role of Anti-GM-CSF Antibodies in Myeloid Cell Functio			HL085453	93.838		346,633.29	346,633.29
		ABCA3 and Alveolar Homeostasis		Vanderbilt University	HL085610	93.838	44.316.54	415.491.15	459.807.69
		Role of SFTPC in Pathogenesis of Interstitial Lung Dise			HL086492	93.838	, , , , ,	437.608.83	437,608.83
		Epidermal Growth Factor Receptor Activation in Pulm Fil			HL086598	93.838		308,051.88	308,051.88
		PPARgamma in the Lung			HL087001	93.838		257,236.87	257,236.87
		Developing Quality Meas Assess Ped Inpt Respiratory Car	Children's Hosp & Reg Med Ct-Seattle		HL088503	93.838		85,454.01	85,454.01
		Surfactant Protein D in Pulmonary and Systemic Host D∈			HL089505	93.838		136,401.92	136,401.92
		Transcriptional Control of Respiratory Epithelial cell			HL090156	93.838		599,497.10	599,497.10
		Regulation of Neutrophil Migration and Polarit			HL090676	93.838		280,755.17	280,755.17
		Immunobiology of IFRD1, a gene modifying CF lung diseas			HL094576	93.838		424,099.09	424,099.09
		Role of C/EBPalpha in CYtoprotection and Recovery from			HL095464	93.838		351,347.62	351,347.62
		Trascriptional Programming of Asthma Related Pathology Late Preterm Birthe, Ureaplasma Species and Childhood L		Queensland University of Technology	HL095580 HL097064	93.838 93.838	46,922.00	560,145.58 499,615.18	560,145.58 594,219.72
		Late Freterin Birtile, Oreapiasina Species and Criticinood E		University of Western Australia	HL097004	93.030	47,682,54	499,013.10	394,219.72
		Lung Injury with Resuscitation of the Pretern		Oniversity of vvestern Adattalia	HL097085	93.838	47,002.54	134,163.50	134,163.50
		Impact of Early Life Diesel Exposure on Immune Patterni		University of Cincinnat	HL097135	93.838	14.287.33	459.111.70	473,399.03
		LPCAT1 is essential for perinatal lung function and sur			HL098319	93.838		449,296.31	449,296.31
		Small Molecule Targeting of NADPH Oxidase in Neutrophil	Phase 2 Discovery, Inc		HL099244	93.838		126,560.72	126,560.72
		Biomarkers of Immunologic Fun	University of Pennsylvania		HL101794	93.838		25,374.64	25,374.64
		Biomarkers of Immunologic Function and Preterm Respiral			HL101800	93.838		236,308.22	236,308.22
		Genetic Analysis of Murine Chronic Hypoxia-Induced Pulm		Indiana University	HL102107	93.838	37,277.00	604,093.68	641,370.68
		FGF and PDGF regulate myofibroblast differentiation in			HL104003	93.838		271,644.60	271,644.60
		Secreted BMP Antagonists in Foregut Organ Developmer			HL105661	93.838 93.838		69,481.45 53,412.48	69,481.45 53.412.48
		Molecular Interventions for Pulmonary Fibrosi		Lung Diseases Research Total	HL107159	93.838	190.485.41	53,412.48 10,276,747,30	53,412.48 10.467.232.71
				Lung Diseases Nessai CII Toldi			130,403.41	10,210,747.30	10,407,232.71

				1	Federal Grant	1 1			
Carr Amamarr	Gov Branch	Award Title	Pass-Through Grantor	Cubraciniant Nama	Number	CFDA	Sub Exp	Fed Exp	Total Exp
Gov Agency	Maternal and Child Health Federal Consolidated Program	Hemophilia Comprehensive Carr	Hemophilia Foundation of Michigai	Subrecipient Name	MC00015	93.110	Sub Exp	13.168.23	13.168.23
	Maternal and Child Realth Federal Consolidated Program	University Affiliated Cincinnati Ctr for Development Di	University of Cincinnat		MC00015 MC00032	93.110		912.287.53	912.287.53
		Increasing Retention in Home Visitation	University of Ciricinnat		MC06632	93.110		36.554.40	36.554.40
		Cincinnati Sickle Cell Newborn Screening Networ		Sickle Cell Affected Fam Greater Cin	MC09233	93.110	6.344.71	176,537.30	182.882.01
		Autism Intervention Research Network on Physical Healt	Massachusetts General Hospita		MC11054	93.110	-,	204.074.98	204,074.98
		Serious Safety Events for Medicaid Children			MC11279	93.110		(4.514.37)	(4.514.37)
		Impact of Cognition on Language in Pedicatric Hearing L			MC21513	93.110		63,678.34	63,678.34
				Maternal and Child Health Federal Consolida	ted Programs Total		6,344.71	1,401,786.41	1,408,131.12
	Maternal and Child Health Services Block Grant to the State	ODH Division of Family Services Regional Outreach Educa			03130011PN	93.994		19,007.51	19,007.51
				Maternal and Child Health Services Block Gr	ant to the			40.000.54	40.000.54
				States Total			•	19,007.51	19,007.51
	Medicaid Transformation Grants	CMS Neonatal Outcomes Gran	University of Cincinnat	MetroHealth Foundation	MS030227	93.793	31,200.00	1.088.18	32.288.18
	Wedicald Transformation Grant	ONO Neorialai Odicorres Gran	Offiversity of Officialitat	Medicaid Transformation Grants Total	WI3030227	33.733	31,200.00	1,088,18	32,288,18
				modicala Transionnation Grants Total			01,200.00	1,000.10	02,200.10
	Medical Assistance Program	Research to Evaluate the Ohio Medicaid Expansio	University of Cincinnat	Washington University	A89070357	93.778	53,088.38	895,092.11	948,180.49
	•	Perinatal Quality Improvement Project and Data Infastru	Ohio State University	, , , , , , , , , , , , , , , , , , ,	Medtapp	93.778		496,270.51	496,270.51
				Medical Assistance Program Total			53,088.38	1,391,362.62	1,444,451.00
	Medical Library Assistance	Increasing Clinical Trial Enrollment: A Semi-Automate			LM010227	93.879		148,809.84	148,809.84
		Shared Task 2010 Analysis of Suicide Notes for Subjective			LM010743	93.879		6,257.33	6,257.33
				Medical Library Assistance Total				155,067.17	155,067.17
	Mental Health Research Career/Scientist Development Awarc	Med Response in Children with Pred Inatt Type ADHI			MH083881	93.281		188.921.81	188.921.81
	Montal Floatal Resource Career, Colonial Sevelophion / Marc	med recoposite in crimaren warr red mak Type resta		Mental Health Research Career/Scientist Dev		00.201		100,021.01	100,021.01
				Awards Total			-	188,921.81	188,921.81
	Mental Health Research Grants	Examining the Biological Basis of ADHI			MH064478	93.242		154,904.61	154,904.61
		Regional Control of Telencephalic Neuronal Diversit			MH069643	93.242		(3,363.54)	(3,363.54)
		Improving Mental Health Outcomes of Child Brain Injur		Case Western Reserve University	MH073764	93.242	341,180.54	305,503.76	706,889.61
				Iowa State University			32,030.82		
		Landa din I Annon de Marine Cometeu		Mayo Clinic	MH073816	93.242	28,174.49	(00 504 40)	(28,564.13)
		Longitudinal Assessment of Maniac Symptom LAMS			MH073816	93.242		(28,564.13) 580,971.16	(28,564.13) 580.971.16
		Family-Focused Treatment for Bipolar Adolescent		University of Cincinnat	MH074033	93.242	9.067.22	122,620,77	131.687.99
		Response Variability in Children with ADHI		Oniversity of Ciricinnat	MH074770	93.242	9,007.22	(4,335.54)	(4,335.54)
		Bipolar Disorder Imaging & Treatment Research Cente	University of Cincinnat		MH077138	93.242		160.520.47	160,520.47
		Neurofunctional & Neurochemical Markers of Treatment Re	University of Cincinnat		MH078043	93.242		(6,313.50)	(6,313.50)
		Anomalous Motor Physiology in ADHE	Kennedy Krieger Research Institute		MH078160	93.242		82,459,51	82,459,51
		Estimating Intracellular Lithium in Brain in vivo by 7l	University of Cincinnat		MH081000	93.242		36,053.55	36,053.55
		Cortical Excitability: Phenotype and Biomarker in ADHI	University of Cincinnat		MH081854	93.242		172,783.32	172,783.32
		Disseminating a Model Intervention to Promote Improved			MH082714	93.242		56,828.04	56,828.04
		2/2 Multisite Study of School Based Treatment Approache			MH082865	93.242		404,903.74	404,903.74
		Medication Continuity in Children Treated for ADHE			MH083027	93.242		163,193.00	163,193.00
		Evaluation of an Intervention for Improving Community-B		Nationwide Childrens Hospita	MH083665	93.242	14,861.74	374,974.70	407,191.05
				University of North Carolina-Chapel Hi			17,354.61		
		Development of a Multifaceted Cognitive Training Program			MH085842	93.242		256,386.83	256,386.83
		Treatment of Maternal Depression in Home Visitatio			MH087499 MH090740	93.242 93.242		422,267.80	422,267.80 331.948.32
		Molecular Mechanisms Controlling Formation of Basal Gan The Effects of Estradiol on genetic Risk for Disordere	Michigan State University		MH090740 MH092377	93.242		331,948.32 4.400.74	331,948.32 4.400.74
		THE ERIOGS OF ESTIAUTOR OF BETTER VISIT OF DISORDER	wiiGrigdii State Utiiversit)	Mental Health Research Grants Total	WI 1092311	33.242	442,669.42	3,588,143.61	4,030,813.03
		OU DI T. I D. I							
	National Bioterrorism Hospital Preparedness Prograi	Ohio Bio-Terrorism Preparednes		Nationwide Childrens Hospita University Hospitals of Cleveland	03130012PP0110	93.889	29,352.26 33.979.71	78,365.30	141,697.27
					Program Total	-	63.331.97	78.365.30	141,697.27
				National Bioterrorism Hospital Preparedness Program Total			00,001.97	10,303.30	141,037.27

			1		F11 01		1		
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Federal Grant Number	CFDA	Sub Exp	Fed Exp	Total Exp
	National Center for Research Resource:	University of Cincinnati Clinical Research Curriculun	University of Cincinnat	•	RR022273	93.389		(430.15)	(430.15)
		Enteric Viral Infections of Captive Rhesus Macaque	Tulane University		RR024871	93.389		11,752.20	11,752.20
		Fentanyl Metabolism			RR025780	93.389		26,436.01	26,436.01
		Cincinnati Ctr for Clin & Trans Sciences & Training CTSA KL2 Scholar Award	University of Cincinnat University of Cincinnat		RR026314 RR026315	93.389 93.389		4,207,397.57 114,919.97	4,207,397.57 114,919.97
		Nikon A1 confocal Microscope	University of Ciricinnat		RR027014	93.389		388,205.00	388,205.00
		AKTA Ready Liquid Chromatography Systen			RR031721	93.389		149.320.99	149,320.99
				National Center for Research Resources Total		-	-	4,897,601.59	4,897,601.59
	National Center on Sleep Disorders Researc	Pediatric Sleep Research Progran			HL078989	93.233		92.945.60	92.945.60
		Vascular Functions in Children w/ Sleep Disorder Breath		University of Cincinnat	HL080670	93.233	41,306.11	419,296.02	460,602.13
		Effect of Adolescent Sleep Restriction on Neural & Beha			HL092149	93.233		348,933.49	348,933.49
		Dynamic Computational Modeling of Obstructive Sleep Apn		University of Cincinnat National Center on Sleep Disorders Research 1	HL105206	93.233	119,430.12 160,736.23	336,718.89 1,197,894.00	456,149.01 1,358,630.23
				National Center on Sleep Disorders Research			160,736.23		
	National Research Service Award in Primary Care Medicin	Institutional Research Training Gran			PE010027	93.186		343,468.47	343,468.47
				National Research Service Award in Primary C	are				
				Medicine Total			-	343,468.47	343,468.47
	Nursing Research	Cortical Reorganization in Children with Unilater:			DC008110	93.361		122,204.20	122,204.20
		Assessing Measurement Bias Impac	University of North Florida		NR010631	93.361		63,632.59	63,632.59
		Dynamical Systems Tools: Modeling multi-leve	University of Rochester		NR010857	93.361		32,724.81	32,724.81
				Nursing Research Total			-	218,561.60	218,561.60
	Oral Diseases and Disorders Research	The role of primary cilia in craniofacial developme			DE019853	93.121		115,070.05	115,070.05
		Global Gene Expression Atlas of Craniofacial Developme		Stowers Institute for Medical Research	DE020049	93.121	1,214.17	382,631.50	383,845.67
				Oral Diseases and Disorders Research Total			1,214.17	497,701.55	498,915.72
	Poison Center Support and Enhancement Grant Program	Poison Control Stabilization and Enhancement Proc			HS15468	93.253		386,298,09	386.298.09
	··	Poison Control Support and Enhancement Grant Program			HS19190	93.253		61,499.80	61,499.80
				Poison Center Support and Enhancement Grar Total	nt Program	_	_	447,797.89	447,797.89
							•	447,797.09	447,757.05
ARR	A Recovery Act / Comparative Effectiveness Research - AHR(Building Modular Pediatric Chronic Disease Registries f		Nationwide Children's Host	HS020024	93.715	12,446.98	1,869,460.05	1,939,495.45
				Univ of Pennsylvania University of Vermont State			22,869.28 34,719.14		
				Recovery Act / Comparative Effectiveness Res	earch -	-	34,719.14		
				AHRQ Total	00.011		70,035.40	1,869,460.05	1,939,495.45
	December of Testinian in Complementary and Alternative Medicin	Controller and Matcheller Found the Formation And For			AT000400	00.040		11.593.98	11.593.98
	Research and Training in Complementary and Alternative Medicir	Soy Isoflavone Metabolite Equol- It's Formation And Fal		Research and Training in Complementary and	AT002190 Alternative	93.213		11,593.98	11,593.98
				Medicine Total			-	11,593.98	11,593.98
	Research on Healthcare Costs, Quality and Outcome	Pursing Perfection in Pediatric Therapeutic		Boston University	HS016957	93.226	65,190,51	918.617.60	1.000.696.23
	resource of the authorite of the state of th	Talong Fortoctor art octable morapoute		University of Cincinnat	110010007	JO.LLO	16,888.12	010,017.00	1,000,000.20
		Step Tools: Developing Web Services for Safe Pediatri			HS017216	93.226		7,618.67	7,618.67
		The Pediatric Emergency Department Experienc		University of Cincinnat	HS019037	93.226	1,536.86	42,023.03	43,559.89
		PHIS+: Augmenting the Pediatric Health Information Syst	Children's Hospital of Philadelphia		HS019862 HS020455	93.226 93.226		81,438.87 16.401.38	81,438.87 16.401.38
		Acceleration to Expertise: Simulation as a Tool to Imp		Research on Healthcare Costs, Quality and Ou		93.220	83,615.49	1,066,099.55	1,149,715.04
				resourch on realmoure costs, quarry and ou	toomed rotal		00,010.40	1,000,000.00	1,140,110.04
	Research Related to Deafness and Communication Disorder	FMRI Genes and Outcome for Cochlear Implants in Infant			DC007186	93.173		73,210.02	73,210.02
		Efficacy of Laryngeal High-Speed Videoendoscop			DC007640	93.173		8,795.64	8,795.64
		Nuclear modifier genes for maternally inherited deafnes A Preclinical Trial of Intratympanic Antivirals for CM ¹			DC007696 DC008651	93.173 93.173		333,140.11 345,314.54	333,140.11 345,314.54
		Inspiratory Muscle Strength Training in Patients with U	Miami University		DC008651 DC009057	93.173		37,343.16	37,343.16
		Molecular Genetics of Usher Syndrome Type	Wildriff Offiversity		DC003037 DC009287	93.173		188.113.58	188.113.58
		Wideband Clinical Diagnosis and Monitoring of Middle-Ea	Boys Town National Research Hospita	Good Samaritan Hospita	DC010202	93.173	33,518.94	229,857.59	263,376.53
		Improved Method of Drug Delivery to the Inner Ea	University of Cincinnat		DC011062	93.173		37,801.06	37,801.06
				Research Related to Deafness and Communica	ntion				
				Disorders Total			33,518.94	1,253,575.70	1,287,094.64
	Sickle Cell Treatment Demonstration Prograr	Sickle Cell Treatment Demonstration Prograr	University of Cincinnat		MC07655	93.365		58,377.36	58,377.36
				Sickle Cell Treatment Demonstration Program	Total	· -	-	58,377.36	58,377.36
	Substance Abuse and Mental Health Services_Projects c	A Continuum of Trauma Care: Adapting Evidence-Based Pra		Toledo Children's Hospita	SM059286	93.243	53,859.89	550,319.32	604,179.21
	Regional and National Significance	Project LAUNCH	Ohio Department of Health	Toledo Offilaren a Floapita	SM059345	93.243	33,038.08	25.550.00	25,550.00
	<u> </u>	•		Substance Abuse and Mental Health Services_					
				Regional and National Significance Total			53,859.89	575,869.32	629,729.21
	Training and Clinical Skills Improvement Project	Enhanced Surveillance for New Vaccine Preventable Disea		Seattle Children's Hospita	IP000147	93.185	23.250.24	485.586.95	521.397.19
	g			University of Cincinnat			12,560.00	,	
				Training and Clinical Skills Improvement Proje	cts Total	-	35,810.24	485,586.95	521,397.19

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
ARRA 1	Trans-NIH Recovery Act Research Suppor	Homeostasis and function of regulatory T cells in agin Genetic Linkage in Lupus		University of Cincinnat Oklahoma Medical Research Fndn	AG033057 AI024717	93.701 93.701	39,861.70 79.895.74	468,058.57	507,920.27 79,895.74
		Characterization of Human Caliciviruse:		Purdue University	AI037093	93.701	63,447.43	421,174.85	484,622.28
		HLA/KIR Region Genetics in Pediatric Arthriti:		Childrens Hosp Oakland	AI067150	93.701	33,347.00	449,183.34	494,943.53
		Ť		University of Cincinnat			12,413.19		
		Regulation of Apoptosis in Activated Primary T Cell			AI057753	93.701		95,220.85	95,220.85
		Epithelial Genes In Allergic Inflammatio			AI070235 AI073713	93.701 93.701		110,265.48 3.470.16	110,265.48 3.470.16
		Behavioral and Virologic Impact of HPV Summer Supplement Identification of Genes Involved in FHLF			AI073713 AI076746	93.701		3,470.16 252.171.86	3,470.16 252.171.86
		Innate Immune Responses During Toxoplasmosi			AI078969	93.701		399,381.49	399,381.49
		Role of IL-15 in the pathogensis of EE		University of Cincinnat	AI080581	93.701	7,775.22	388,159.26	395,934.48
		Neuronal Regulation of HSV Lytic and Latent Infectio		•	AI081083	93.701		61,189.63	61,189.63
		Rare Diseases Clinical Consortia for the Rare Disease	University of California		AI082973	93.701		129,431.49	129,431.49
		RELM Peptides Alter Lung Defense Unbiased Forward Genetic Analysis of Virus/Host Interac		University of Cincinnat	AI083599 AI087336	93.701 93.701	151,409.60	214,868.28 166.194.21	214,868.28 317.603.81
		A Multi-center Clinical Trial of 1760 MCG of Daily Swa		Children's Hospital of Philadelphia	AI087336 AI088806	93.701	151,409.60	166,194.21 313,484.15	317,603.81
		A Middle-Center Clinical That of 1700 MCC of Daily Swa		The Children's Hospital Association	Alooooo	33.701	23,200.00	313,404.13	391,003.13
				University of Utah			44,025.64		
		Cincinnati Rheumatic Diseases Cente			AR047363	93.701		369,425.31	369,425.31
		Early Aggressive Therapy in Juvenile Idiopathic Arthri	Children's Hosp & Reg Med Ct-Seattle		AR049762	93.701		85,901.90	85,901.90
		Efficacy Measures in Pediatric Lupus (Supplement			AR055054 AR058587	93.701 93.701		46,453.49	46,453.49
		Defining the complex genetics of Juvenile Idiopathic A Development and Validation of a Disease-Specific Sever	Indiana Univ - Purdue Univ @ Inpls		AR058587 AR058767	93.701		471,078.64 1,000.00	471,078.64 1,000.00
		CARRA: Accelerating Toward an Evidence Based Culture i	Duke University		AR058934	93.701		456,160.21	456,160.21
		Children's Oncology Group Phase	Children's Oncology Group		CA097452	93.701		103,001.53	103,001.53
		Children's Oncology Group Chair's Gran	Children's Oncology Group		CA098543	93.701		46,559.86	46,559.86
		Role and Regulation of the Human DEK Proto-Oncogen			CA116316	93.701		88,160.47	88,160.47
		Improving Parent/Adolescent Communication about Tobacci			CA117864	93.701		18,860.15	18,860.15
		Rac GTPases as Targets in Lymphomagenesi Prediction Model for Radiation Sensitivity in Children		University of Cincinnat Emory University	CA125658 CA139275	93.701 93.701	20,994.21 3.361.80	144,743.10 136,639.93	165,737.31 180,285.20
		Frediction woder for Radiation Sensitivity in Children		Univ of Texas M D Anderson Cancer Cnt	CA139275	93.701	23.478.37	130,039.93	100,203.20
				University of Cincinnat			5,477.63		
				Vanderbilt University			11,327.47		
		The Role of MLL-AF9 in Acute Myeloid Leukemia			CA140518	93.701		181,471.03	181,471.03
		Cincinnati Neuro-Oncology Research Core			CA149239	93.701		459,500.21	459,500.21
		Expanding the Ohio IMmunization Registry to Include BN Metabolic Consequences of Substance Use in Adolescent C	Hamilton County Public Health		CPPW Ham Co - ARRA DA025312	93.701 93.701		164,559.76 174.483.35	164,559.76 174.483.35
		Nuclear modifier genes for maternally inherited deafnes			DC007696	93.701		7,943.16	7,943.16
		Administrative Supplement-A Preclinical Tria			DC007650 DC008651	93.701		82,355.14	82,355.14
		Wideband Clinical Diagnosis and Monitoring of Middle-Ea			DC010202	93.701		111,926.48	111,926.48
		Studies of Gaucher Disease: A Prototype Lipidosi			DK036729	93.701		100,622.03	100,622.03
		Expression and Function of the Guanylin Ligand Famil			DK047318	93.701		286,439.60	286,439.60
		Behavioral & Nutrition TX to Help CF Preschoolers Grov Behavioral Rx & Nutrition in Pediatric Chronic Diseas		University of Arizona	DK054915 DK059492	93.701 93.701	24,462.12	12,842.61 22,465,17	37,304.73 22.465.17
		Clinical Center for Cholestatic Liv Disease in Childre			DK059492 DK062497	93.701		22,465.17 91,181.35	22,465.17 91,181.35
		Chronic Kidney Disease in Children (CKiD	Children's Mercy Hospita		DK062437 DK066143	93.701		30,189.66	30,189.66
		Mechanistic Analysis of Eosinophilic Esophagiti:			DK067255	93.701		14,013.22	14,013.22
		Intralumenal Effects in Cholesterol Absorptio			DK068463	93.701		45,176.62	45,176.62
		Self-Management of Type 1 Diabetes During Adolescenc			DK069486	93.701		12,630.53	12,630.53
		Adolescent Bariatrics: Assessing Health Benefits & Ris		Baylor College of Medicine	DK072493	93.701	4,278.70	280,318.61	284,597.31
		Adolescent Bariatrics: Assessing Health Benefits & Risl RIVUR Supplement	University of Buffalo		DK072493 DK074063	93.701 93.701		60,971.78 (1,295.15)	60,971.78 (1,295.15)
		Comparative Effectiveness of Pediatric Eosinophilic Eso	On Colory of Dunaio		DK074003 DK076893	93.701		656,641.93	656,641.93
		Dig Health Ctr: Bench to Bedside Res in Ped Dig Diseas			DK078392	93.701		132,451.23	132,451.23
		SubClinical Cardiovascular disease in Youth (CVE	University of Colorado		DK078542	93.701		350,549.20	350,549.20
		Adolescent Bariatrics: Controlled Longitudinal Study of			DK080020	93.701		73,605.69	73,605.69
		Mammalian Foregut and Liver Developmer Glomerulosclerosis in Human FSGS and Animal Model			DK080823 DK081489	93.701 93.701		52,840.16 354,970.63	52,840.16 354,970.63
		Immunosuppression Withdrawal for Stable Pediatric Live	The Univ of California, San Francisco		DK081469 DK083031	93.701		42,713.85	42,713.85
		Calcineurine Inhibitor Minimization and FOXP3+ Treq	Children's Hospital of Philadelphia		DK087270	93.701		127,506.77	127,506.77
		Model systems for hematologic disorders caused by ribos	University of Cincinnat		DK087680	93.701		10,721.77	10,721.77
		Nextgen Dissection of the Genomic Basis of Kidney Devel			DK090891	93.701		263,738.39	263,738.39
		Diesel, Allergens and Gene Interactions and Child Atoph	University of Cincinnat		ES011170	93.701		159,649.65	159,649.65
		Neurobehavioral Effects of Inseticide Exposure in Pregn		University of Cincinnat	ES015517 ES016830	93.701 93.701	23,992.14 22,699.65	657,818.32 113,346.71	681,810.46 136,046.36
		Exposure-induced Systemic Oxidative Stress in Children BPA Go Grant	University of Rochester	University of Cincinnat	ES016830 ES018736	93.701	22,099.65	113,346.71	136,046.36
		CRIM1-b-Catenin-Cadherin Interactions in Eye Developmer	On Cooky of Nocioester		EY019377	93.701		332,298.38	332,298.38
		Genomic Analysis of Pediatric SIRS and Septic Shoc		University of Cincinnat	GM064619	93.701	122,059.60	56,948.36	179,007.96
		Evolution of Canalizing Mechanisms in Gene Expressio	The University of Chicago		GM078381	93.701		62,756.94	62,756.94
		Aspects of Blastocysts			HD012304	93.701		39,437.88	39,437.88
		CCHMC Pediatric Pharmacology Research Uni			HD037249 HD038578	93.701 93.701		(5,009.29) 77,081.39	(5,009.29) 77.081.39
		Recovery Act Administrative Supple-Languag Preventing Teen Pregnancy: Prepregnancy Psychosocial Me			HD038578 HD052533	93.701 93.701		77,081.39 7,605.00	77,081.39 7,605.00
		Molecular Signaling in Decidualizatio			HD052533	93.701		440,164.86	440,164.86
								,	,

					Federal Grant				
Gov Agency	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Number	CFDA	Sub Exp	Fed Exp	Total Exp
		Novel genetic and salivary glycan biomarkers for risk (University of Alabama - Birminghan	HD059140	93.701	17,301.02	10,284.60	27,585.62
		Therapy of Neuronopathic Gaucher Diseas			HD059823	93.701		6,260.29	6,260.29
		The Roles of Steel Factor in Germ Cell Behavior in th			HD060578	93.701		430,203.42	430,203.42
		Mediating Factors in the Relationship between Obesity a		University of California	HD063275	93.701	27,440.92	145,039.91	172,480.83
		Develop of Phone and Quest Scrig Protocol for Res in ASI			HD065277	93.701		441,456.02	441,456.02
		ASPE Portfolio on Comparative Effectiveness Research an Role of FA Protein Complexes in Hematopoiesi			HHSP233201000162A HL076712	93.701 93.701		25,000.00 (2,545.94)	25,000.00
		Role of Rb Family in Lung Epithelial Response to Injur			HL079193	93.701		(2,545.94) 54,256.90	(2,545.94) 54,256.90
		Molecular Mechanism of Severe Congenital Neutropeni			HL079574	93.701		58,701.43	58,701.43
		Function and Regulation of FANCM in Fanconi Anemia			HL084082	93.701		93.913.24	93.913.24
		Mechanisms Linking Metastasis to Tumor Procoagulant an			HL085545	93.701		114,127.12	114,127.12
		FANCD2 Monoubiquitination in DNA Damage Response:			HL085587	93.701		101.650.40	101.650.40
		Administrative Supplement Providing Summer Researc			HL086598	93.701		181,920.78	181,920.78
		Rac GTPase Inhibition in Chronic Myelogenous Leukemi			HL087159	93.701		106,143.38	106,143.38
		Role of the embryonic node in cardiac development and c			HL088639	93.701		104,107.69	104,107.69
		An Animal Model of Hemophagocytic Lymphohistiocytosi			HL091769	93.701		153,165.79	153,165.79
		Mechanism of Vasopressin-Mediated Placental Vascular Re			HL093683	93.701		22,002.92	22,002.92
		Notch signaling in heart valve development and diseas			HL094319	93.701		425,125.86	425,125.86
		Effects of IL-4 and IL-13 on Pulmonary Smooth Muscle ii			HL097360	93.701		342,940.51	342,940.51
		Unbiased genome-wide screen to identify genes regulatir			HL100315	93.701		506,424.61	506,424.61
		Pulmonary Progenitor Cells	Oregon Health Sciences University		HL100371	93.701		170,606.42	170,606.42
		Pediatric Sepsis Biomarker Risk Mode		Nationwide Children's Host	HL100474	93.701	1,500.00	525,120.32	526,620.32
		Development of an Asthma Research Core Cente	University of Michigan		HL101333 MH089721	93.701 93.701		607,132.90 156.034.91	607,132.90 156,034.91
		Develop of a Brief Screener for Research Diagnoses ASI Mitogenic Activities in Neurofibromatosi	University of Michigan		NS028840	93.701		42,776.59	42,776.59
		Drug and Non-Drug Treatment of Pediatric Chronic Headac			NS050536	93.701		14,215.53	14,215.53
		Epilepsy Phenome/Genome Projec	The Univ of California, San Francisco		NS053998	93.701		71,648.62	71,648.62
		Cincinnati Center for Neurofibromatosis Researc	The only of California, Carr rancisco	University of Cincinnat	NS057531	93.701	136.038.54	(30,770.19)	105,268.35
		Therapy of Gaucher Disease: In Vivo Enhancemen			NS064352	93.701	,	217,221.25	217,221.25
		Short and long-term impact of neonatal seizures on hipp			NS064378	93.701		73,027.31	73,027.31
		The Ohio State University Center for Clinical and Trans	Ohio State University		RR025755	93.701		73,108.20	73,108.20
		Illumina iScan System for the OMRF Microarray Research			RR027190	93.701		411,859.60	411,859.60
		Enterprise Research Data Storage for Data-Intensive Com			RR027230	93.701		500,000.00	500,000.00
		ARRA Fogarty			TW007988	93.701		3,476.32	3,476.32
				Trans-NIH Recovery Act Research Support To	otal		916,687.69	17,759,966.99	18,676,654.68
	Trans-NIH Research Support	Open Source Science: Transforming Chronic Illness Car		University of California	DK085719	93.310	26,520.10	1,538,274.26	1,609,638.66
	Trans transcalar suppor	Open Course Colonico. Transforming Official military Cal		University of Chicago	511000710	55.515	66.460.75	1,000,214.20	1,000,000.00
				University of Vermont State			(21,616.45)		
		RAMPART Hamilton Schwartz	University of Cincinnat	,	NS056975	93.310	(= 1,0 101.0)	16.669.68	16.669.68
				Trans-NIH Research Support Total			71,364.40	1,554,943.94	1,626,308.34
		11000 0			00 BB0000			E10.101.00	=10.101.00
	University Centers for Excellence in Developmental Disabilitie	UCDD Program	University of Cincinnat	University Centers for Excellence in Develop	90 DD0638	93.632		510,134.96	510,134.96
	Education, Research, and Service			Education, Research, and Service Total	nental Disabilities			510,134.96	510,134.96
	Education, Research, and Service			Education, Research, and Service Total				310,134.90	310,134.90
	Vision Research	Targeting Survival Factors for Ocular N\	The Johns Hopkins University		EY012609	93.867		5.560.13	5.560.13
	VISION NOSCERCI	Ocular HSV Infection-Latency and Pathogenesis	University of Cincinnat		EY013168	93.867		151,475.96	151,475.96
		Investigation of Mammalian Retinal Neuron Developmer	Critically of Circumsta		EY013612	93.867		361,076.37	361,076.37
		Molecular Mechanisms of Retinal Determination Protein			EY014648	93.867		368,396.80	368,396,80
		Wnt Pathway Regulation of Lens Polarit			EY016241	93.867		162,447.32	162,447.32
		RhoGTPases in Early Eye Developmen			EY017848	93.867		288,971.69	288,971.69
		Pros/Prox1 and Lens Development in Drosophil			EY017907	93.867		330,089.88	330,089.88
		Cell-Cell Signaling During Mammalian Early Eye Formatio			EY018097	93.867		378,923.27	378,923.27
		Eyes Absent Phosphatase Inhibitors In Eye Diseas			EY019125	93.867		154,067.86	154,067.86
				Vision Research Total				2,201,009.28	2,201,009.28
				Dept of Health and Human Serv Total			10,671,436.85	120,339,145.79	131,010,582.64
		Alcohol and Drug Services				93.959		342,124.00	342,124.00
		Maternal Depression				93.243		120,127.70	120,127.70
				Grand Total		-	\$ 11,046,016.71 \$	124,419,080.69 \$	135,465,097.40
							,, 🗸	.,,	,,

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2011

1. SCOPE OF AUDIT

All Federal grant operations of Children's Hospital Medical Center ("the Medical Center"), are included in the scope of the Office of Management and Budget (OMB) Circular A-133 audit (the "single audit"). Single audits are performed in accordance with the provisions of the OMB's Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as the Medical Center's cognizant Medical Center for the single audit.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplementary Schedule of Expenditures of Federal Awards includes the Federal grant activity of the Medical Center and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic combined financial statements.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2011.

* * * * * *



Deloitte & Touche LLP 250 E. 5th Street Suite 1900 Cincinnati, OH 45202-5109 USA

Tel: +1 513 784 7100 Fax: +1 513 784 7204 www.deloitte.com

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

To the Board of Trustees of Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

We have audited the combined financial statements of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") as of and for the year ended June 30, 2011, and have issued our report thereon dated October 25, 2011, which report expressed an unqualified opinion. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States.

Internal Control Over Financial Reporting

In planning and performing our audit, we considered Cincinnati Children's' internal control over financial reporting as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Cincinnati Children's' internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's' internal control over financial reporting.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis.

Our consideration of internal control over financial reporting was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over financial reporting that might be deficiencies, significant deficiencies or material weaknesses. We did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses, as defined above.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Cincinnati Children's' financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

This report is intended solely for the information and use of the Board of Trustees, management, others within the entity, federal awarding agencies, and pass- through entities, and is not intended to be and should not be used by anyone other than these specified parties.

Deloite & Tarche LLP



Deloitte & Touche LLP 250 E. 5th Street Suite 1900 Cincinnati, OH 45202-5109

Tel: +1 513 784 7100 Fax: +1 513 784 7204 www.deloitte.com

REPORT ON COMPLIANCE WITH REQUIREMENTS THAT COULD HAVE A DIRECT AND MATERIAL EFFECT ON EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE IN ACCORDANCE WITH OMB CIRCULAR A-133

To the Board of Trustees of Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

Compliance

We have audited the compliance of Cincinnati Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") with the types of compliance requirements described in the *OMB Circular A-133 Compliance Supplement* that could have a direct and material effect on each of Cincinnati Children's major federal programs for the year ended June 30, 2011. Cincinnati Children's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs. Compliance with the requirements of laws, regulations, contracts, and grants applicable to each of its major federal programs is the responsibility of Cincinnati Children's management. Our responsibility is to express an opinion on Cincinnati Children's compliance based on our audit.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Cincinnati Children's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Our audit does not provide a legal determination of Cincinnati Children's compliance with those requirements.

In our opinion, Cincinnati Children's complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2011.

Internal Control Over Compliance

Management of Cincinnati Children's is responsible for establishing and maintaining effective internal control over compliance with the requirements of laws, regulations, contracts, and grants applicable to federal programs. In planning and performing our audit, we considered Cincinnati Children's internal control over compliance with the requirements that could have a direct and material effect on a major federal program to determine our auditing procedures for the purpose of expressing our opinion on compliance, and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be deficiencies, significant deficiencies, or material weaknesses. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above.

This report is intended solely for the information and use of the Board of Trustees, management, others within the entity federal awarding agencies, and pass-through entities and it is not intended to be and should not be used by anyone other than these specified parties.

Deloite & Tarche LLP

October 25, 2011

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2011

PART I. SUMMARY OF AUDITOR'S RESULTS Financial Statements: Unqualified Type of auditor's report issued: Internal control over financial reporting: Material weakness(es) identified? Yes X No None Significant deficiency(ies) identified? Yes X reported Noncompliance material to financial statements noted? Yes X No Federal Awards: Internal control over major programs: X No Material weakness(es) identified? Yes Significant deficiency(ies) identified? None Yes X reported Unqualified Type of auditor's report issued on compliance for major programs: Any audit findings disclosed that are required to be reported accordance with section 510(a) of OMB Circular A-133? Yes X No Identification of Major Programs: **CFDA Number** Name of Federal Program or Cluster Research and Development* Various Children's Hospital Medical Center has determined that its entire research and development program inclusive of all research and development grant activity should be considered clustered and as such, constitutes one major program. Dollar threshold used to distinguish between Type A and Type B programs?

Auditee qualified as low-risk auditee? X Yes No

Research and Development program tested as a single Type A program

\$ 3,000,000

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

PART II. FINANCIAL STATEMENT FINDINGS SECTION

2011 Findings

No findings are reportable for fiscal year 2011.

2010 Findings

No findings are reportable for fiscal year 2010.

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS SECTION

2011 Findings

No findings are reportable for fiscal year 2011.

2010 Findings

No findings are reportable for fiscal year 2010.